Check all of this and tell me the exact truth

Reading File

Browsing Directory

/tmp/workspace

Browsing Directory

~/attachments/e002d634-63d6-42ae-a2c4-307307082f98

Running Command

python3 - <<'PY' from docx import Document from pathlib import Path base=Path('/tmp/workspace/attachments/e002d634-63d6-42ae-a2c4-307307082f98') for f in sorted(base.glob('*.docx')): print('\n'+'='*100+'\nFILE:',f.name) d=Document(f) print('CORE:', d.core_properties.author, '|',d.core_properties.created,'| modified:',d.core_properties.modified) for i,p in enumerate(d.paragraphs,1): if p.text.strip(): print(f'P{i} [{p.style.name}]: {p.text}') for ti,t in enumerate(d.tables,1): print(f'-- TABLE {ti} --') for row in t.rows: print(' | '.join(c.text.replace('\n',' / ') for c in row.cells)) PY

Running Command

mkdir -p "/tmp/workspace/doc-verification/extracted" && python3 - <<'PY' from docx import Document from pathlib import Path base=Path('/tmp/workspace/attachments/e002d634-63d6-42ae-a2c4-307307082f98') out=Path('/tmp/workspace/doc-verification/extracted/all_documents.txt') with out.open('w',encoding='utf-8') as o: for f in sorted(base.glob('*.docx')): o.write('\n'+'='*100+'\nFILE: '+f.name+'\n') d=Document(f) cp=d.core_properties o.write(f'CORE: author={cp.author!r}; created={cp.created}; modified={cp.modified}; last_modified_by={cp.last_modified_by!r}\n') for i,p in enumerate(d.paragraphs,1): if p.text.strip(): st=p.style.name if p.style else 'None' o.write(f'P{i} [{st}]: {p.text}\n') for ti,t in enumerate(d.tables,1): o.write(f'-- TABLE {ti} --\n') for row in t.rows: o.write(' | '.join(c.text.replace('\n',' / ') for c in row.cells)+'\n') print(out) PY

Reading File

Running Command

python3 - <<'PY' from docx import Document from pathlib import Path base=Path('/tmp/workspace/attachments/e002d634-63d6-42ae-a2c4-307307082f98'); out=Path('/tmp/workspace/doc-verification/extracted') for f in base.glob('*.docx'): d=Document(f); fn=out/(f.stem+'.txt') with fn.open('w') as o: for i,p in enumerate(d.paragraphs,1): if p.text.strip():o.write(f'P{i}: {p.text}\n') for ti,t in enumerate(d.tables,1): o.write(f'\nTABLE {ti}\n') for r in t.rows:o.write(' | '.join(c.text.replace('\n',' / ') for c in r.cells)+'\n') print(fn) PY python3 "/tmp/skills/docx/scripts/office/unpack.py" "/tmp/workspace/attachments/e002d634-63d6-42ae-a2c4-307307082f98/Metric_Specification_v3.docx" "/tmp/workspace/doc-verification/metric_unpacked" && python3 "/tmp/skills/docx/scripts/office/unpack.py" "/tmp/workspace/attachments/e002d634-63d6-42ae-a2c4-307307082f98/v2_Verification_Report.docx" "/tmp/workspace/doc-verification/v2_unpacked"

Reading File

Searching the Web

Margin of Exposure regulatory toxicology BMDL NOAEL reference point EFSA guidance

Reading File

Finding Sources

Searching PubMed

drug exposure response systematic review

Searching the Web

site:labeling.pfizer.com Rapamune prescribing information 12.3 blood plasma ratio 36 18 protein binding 92

Searching the Web

Rivera 1996 1997 PNAS 94 7825 mammalian three hybrid rapamycin gene expression EC50

Running Command

python3 - <<'PY' from docx import Document from pathlib import Path base=Path('/tmp/workspace/attachments/e002d634-63d6-42ae-a2c4-307307082f98') for f in base.glob('*.docx'): print('\n###',f.name) d=Document(f) for ti,t in enumerate(d.tables,1): print('\nTABLE',ti) for ri,r in enumerate(t.rows,1): print('ROW',ri,' || '.join(' '.join(c.text.split()) for c in r.cells)) PY

Searching PubMed

auxin inducible degron 2 OsTIR1 F74G

Searching PubMed

super-sensitive auxin inducible degron F74A

Searching PubMed

Cosmetics-triggered percutaneous remote control transgene expression mice

Searching PubMed

Feil CreERT2 4-hydroxytamoxifen EC50

Searching PubMed

Iwamoto trimethoprim destabilizing domain

Searching PubMed

Rivera rapamycin inducible gene expression translocation mammalian three hybrid

Reading Article

PMID: 9223271

Reading Article

PMID: 25943548

Reading Article

PMID: 32941625

Searching PubMed

"auxin-inducible degron 2 technology"

Finding Sources

Reading Article

PMID: 33177522

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC21513/

Searching PubMed

endoxifen CreERT2 activation

Reading Article

PMID: 27077909

Exact truth

These are not independent verification documents. They are a chain of internally consistent, machine-assembled drafts, created on the same date, which repeatedly validate one another while still carrying unresolved source-level errors. The Status Ledger itself correctly admits this.

The reliable conclusion is:

Some arithmetic is correct.
A few cited facts are externally corroborated.
Several headline biological and methodological claims are still unverified, overstated, or invalidly framed.
The material is not ready for submission, presentation as verified research, or clinical/safety conclusions.

What is genuinely supported

1. The sirolimus blood-to-plasma correction is real

The documents' claim that sirolimus is extensively partitioned into blood cells is supported by the FDA-approved Rapamune label: mean blood-to-plasma ratio 36 ± 18, approximately 92% plasma-protein binding, chiefly albumin, with therapeutic monitoring based on whole-blood concentrations. The conversion is arithmetically correct:

4 to 20 ng/mL whole blood divided by 36 = 0.111 to 0.556 ng/mL plasma
At MW 914.2, this is about 0.121 to 0.608 nM plasma

The relevant FDA label confirms the stated pharmacokinetic facts in its Rapamune labeling.

But this does not validate the final sirolimus MoE of 3.3 to 17. The denominator conversion is supported, but the numerator, described as a 2 nM functional EC50, has not been demonstrated from the primary source. The documents themselves admit that the exact functional EC50 needs extraction from the original paper.

Also, the cited paper is misattributed. PNAS 94:7825 is by Liberles, Diver, Austin, and Schreiber, not Rivera et al. It reports a nontoxic rapamycin derivative inducing targeted expression with an EC50 below 10 nM, not a documented 2 to 5 nM sirolimus activation EC50. See the original PNAS abstract.

2. The basic calculations shown are mostly correct

The following arithmetic checks out:

10 ÷ 7,000 = 0.00143
10 ÷ 482 = 0.0207
10 ÷ 27 = 0.370
2 ÷ 0.608 = 3.29
6 ÷ 10.7 = 0.561
300 ÷ 600 = 0.50
(P(\geq1)=1-(1-p)^n) is the correct formula under independent, constant annual event probability.

This establishes only that the divisions and probability formula are right. It does not establish that the biological concentrations are comparable or that their interpretation is valid.

3. The engineered AID comparison was invalid as originally calculated

This correction is sound in principle:

AID2 uses OsTIR1(F74G) with 5-Ph-IAA.
The super-sensitive system uses OsTIR1(F74A) with 5-Ad-IAA.
Comparing a response threshold for a synthetic ligand with human exposure to natural IAA is not a valid ligand-for-ligand margin calculation.

The AID2 paper confirms its bump-and-hole design and reports no detectable leaky degradation with the engineered pair. See the AID2 abstract. The super-sensitive AID paper confirms the engineered 5-Ad-IAA and OsTIR1(F74A) system and the large decrease in inducer concentrations required. See the super-sensitive AID paper.

The document is also correct that the super-sensitive paper reports interactions with natural IAA in the 10 to 100 µM range in its yeast two-hybrid assay. However, that is not automatically a mammalian functional degradation threshold. It cannot be treated as a clinically meaningful human-exposure safety margin without much more assay-specific justification.

4. The Wang paraben study exists and supports a limited claim

The 2015 Wang et al. study is real. It showed that topical, commercial paraben-containing products could control expression from subcutaneous designer-cell implants in mice. The authors describe this as a mouse proof-of-concept, not evidence that routine human cosmetic use unintentionally activates therapeutic switches. The study abstract supports the mouse finding.

So this statement is defensible:

Commercial paraben-containing cosmetics activated a designed transgene switch in subcutaneous implants in mice under the study's experimental conditions.

This statement is not defensible:

Routine cosmetic use creates a demonstrated human inadvertent-activation risk.

No supplied document establishes human exposure at the implant site, a human activation threshold, or real-world human activation.

What is false, misleading, or not established

1. The claim that regulatory MoE should be anchored to the “lowest observed activation concentration” is too strong

The v3 document says regulatory margins are built from the lowest concentration at which activation is observed, calling it the “activation analogue of a LOAEL.”

That is an oversimplification and should not be presented as standard regulatory doctrine.

Regulatory risk assessment commonly uses a point of departure, often a benchmark-dose lower confidence limit (BMDL), and sometimes a NOAEL or LOAEL depending on the evidence. EFSA specifically describes BMDL as its preferred reference point because it uses dose-response information. See EFSA's MoE statement and its benchmark-dose guidance.

The documents are right about one narrower point: a binding Kd and a functional activation endpoint are not interchangeable. But it does not follow that the first observed concentration in an in-vitro switch assay is the uniquely correct regulatory reference point.

A “lowest effective concentration” can be highly dependent on:

assay sensitivity
number and spacing of tested doses
exposure duration
target protein and expression level
cell type
readout threshold
whether the result was replicated

It is not inherently more valid than EC50. It is merely a different endpoint.

2. Calling the proposed metric “Margin of Exposure” is potentially misleading

The formula in v3 is:

concentration causing activation in vitro ÷ maximum plausible human exposure

That is a screening ratio, not automatically a regulatory MoE in the usual toxicological sense. Regulatory MoEs normally involve an adverse-effect point of departure, exposure estimates with defined duration and route, uncertainty assessment, and often species extrapolation.

Here, the numerator is often a construct-specific activation concentration rather than an adverse biological effect. The denominator is frequently plasma or blood concentration rather than concentration at the engineered cell, graft, or intracellular receptor site.

A safer label would be something like:

“Exploratory exposure-to-functional-activation ratio”

or

“In-vitro activation-to-systemic-exposure screening ratio.”

Using “MoE” is possible only if the report explicitly states that it is an adapted, non-regulatory screening application and not a formal human safety MoE.

3. The documents repeatedly overstate comparability of in-vitro and human concentrations

The central calculation compares in-vitro functional thresholds with systemic human Cmax or trough concentrations. That may be useful for hypothesis generation, but it cannot establish real activation or safety in a therapeutic graft.

Major missing variables include:

free versus total drug concentration
tissue and graft distribution
intracellular concentration
protein binding and nonspecific binding
exposure duration
concentration-time profile
blood-cell partitioning
local route of administration
receptor abundance
construct expression and target turnover
assay cell type and media composition

The v3 document says plasma concentration is a “proxy for graft-site concentration throughout.” That is a major unvalidated assumption, not a minor caveat. It means most rows remain exploratory at best.

4. The endoxifen row is invalid as calculated

This is the clearest unresolved defect in v3.

The documents calculate an endoxifen margin using the 4-OH-tamoxifen CreERT2 threshold of 6 nM. They later identify their own error correctly: endoxifen is a different ligand, so its concentration should not be compared with a 4-OHT activation threshold without direct evidence that the threshold is interchangeable.

The evidence does support that endoxifen can activate CreERT2 and is a useful inducer, but it does not support importing the precise 4-OHT EC50. In fact, the available 2016 study says endoxifen induced about half the ERT2-fusion activity compared with fresh trans-4-OHT under its tested conditions, confirming that equivalence should not be assumed. See the Felker et al. abstract.

Exact result: the claimed endoxifen MoE of 0.056 to 0.16 must be removed or labeled not calculable until an endoxifen-specific concentration-response result for the same CreERT2 construct and experimental context is sourced.

5. The doxycycline result is not one clean result

The documents mix:

low-dose steady-state concentration
low-dose Cmax
single-dose Cmax
possibly distinct dosing conditions

into one wide 482 to 7,000 ng/mL range. That produces a dramatic margin range but does not describe one clinically coherent exposure scenario.

The v3 rule itself says high-dose and alternative regimens should be separate rows. Doxycycline must be separated the same way trimethoprim was separated. Until that is done, the “50 to 700-fold” framing is not a single interpretable finding.

6. The wild-type AID conclusion is not established

The statement:

Endogenous circulating IAA exceeds the lowest reported activation concentration for wild-type OsTIR1, therefore background auxin would be expected to produce partial constitutive degradation.

is not proven.

Even if both numerical values are accurately quoted:

The 300 nM DC50 and 100 to 500 µM working concentration may derive from different assays.
A DC50 depends on target, cell line, OsTIR1 expression, AID tag, duration, and readout.
Circulating endogenous IAA is not necessarily the relevant concentration inside the engineered cells.
The relevant biological system may use culture medium, serum, cellular uptake, or local production, none of which follows directly from a plasma value.
The claimed endogenous IAA values need primary analytical-method verification.

Therefore, the correct statement is:

Published values raise a hypothesis that background IAA could be relevant for some wild-type AID implementations, but the supplied evidence does not establish constitutive or partial degradation in a human therapeutic setting.

The AID2 paper does support the narrower claim that basal degradation from indole chemicals in culture medium was a design problem and that the engineered system was intended to reduce it. It does not establish the documents’ human plasma MoE claim.

7. “Only in-vivo demonstration with an off-the-shelf consumer product in the whole set” is unsupported

That may be true for the authors' selected set of papers, but the documents do not show a systematic search, a reproducible inclusion framework, or enough evidence to support the word “only.”

Replace it with:

“An identified in-vivo demonstration in the reviewed set.”

8. “The field solved exposome orthogonality twice without naming it” is rhetoric, not a verified finding

It may be an interesting interpretation, but it is not a factual result unless the authors systematically define:

“exposome orthogonality”
what counts as a solution
what literature was searched
why these two cases qualify
whether other relevant systems were excluded

It belongs in the Discussion as a cautious conceptual proposal, not as a conclusion stated as fact.

9. “Systematic scoping review” is not an accurate description yet

Calling this a PRISMA-ScR scoping review does not make it one.

The documents shown do not provide:

a protocol registered or dated before selection and extraction
databases searched
search strings
search dates
eligibility criteria
duplicate screening process
selection flow diagram
data-extraction form
source-of-evidence appraisal method
a record-level reference table
reproducible handling of conflicting endpoints

The documents say the endpoint rule must be written before extraction, but the rule was plainly developed after the data table and verification report existed. That is post-hoc for the current dataset. It can govern a future re-extraction, but not retroactively make the existing selection pre-specified.

10. The annual probability calculation is mathematically correct but presently scientifically weak

The formula assumes constant, independent annual probability. The documents recognize this limitation, but their statement about the direction of error is too categorical.

With between-person heterogeneity and repeated-event clustering, the simple formula may not describe either population risk or individual risk well. The direction and magnitude of bias depend on the distribution of annual risk, temporal dependence, and how “event” is defined.

It is acceptable as an illustrative sensitivity grid, but not as an estimate of patient-level cumulative probability without actual longitudinal prescribing or exposure data.

Document integrity concerns

All four documents have the same creation date, 21 September 2026, and the same same-day workflow language. Their statements of independent verification are not independent evidence.

The Status Ledger is unusually candid and correct on this point:

“Every document feeding this ledger ... was machine-assembled. They are not independent of one another.”

That is the most accurate sentence in the entire packet.

Also, one citation error is already demonstrable:

The documents repeatedly name “Rivera et al. 1997, PNAS 94:7825.”
The actual article is Liberles SD, Diver ST, Austin DJ, Schreiber SL.
It reports an EC50 below 10 nM for a nontoxic rapamycin derivative in a mutant FRB system, not the established 2 to 5 nM sirolimus functional threshold used in the table.

This matters because the sirolimus row is treated as one of the load-bearing corrected examples.

Bottom line by row

Row	Exact current status
Tet-On / doxycycline	Suggestive concern, but must be split by coherent regimen and verified against the primary activation assay. Not a definitive clinical activation finding.
ecDHFR-DD / trimethoprim	Numerically reproducible but the 10 µM value is a saturating working concentration, not a validated onset threshold. Exploratory only.
FKBP-FRB / sirolimus	Blood-to-plasma conversion is supported. Functional numerator is not verified and appears wrongly attributed. Do not claim MoE 3.3 to 17 as established.
ERT2 / 4-OHT	Plausible exploratory comparison, but construct-specific threshold, compartment, and exposure comparability remain unresolved.
ERT2 / endoxifen	Invalid as calculated. Must be not calculable until endoxifen-specific activation data are obtained.
iCasp9 / rimiducid	Correctly not calculable from the supplied material.
Wild-type AID / endogenous IAA	Hypothesis-generating only. No demonstrated human therapeutic activation or partial constitutive degradation.
AID2 / 5-Ph-IAA	Correctly not calculable for human environmental exposure based on the supplied evidence.
Super-sensitive AID / 5-Ad-IAA	Correctly not calculable for human environmental exposure based on the supplied evidence.
Agricultural auxins	Correctly an evidence gap. Food residue limits do not establish systemic concentration at the target system.
Propylparaben switch	Strong mouse proof-of-concept that a commercial cosmetic can activate an implant switch under experimental conditions. It does not show routine human inadvertent activation.

The truthful final conclusion

The project contains a potentially useful screening framework for identifying engineered control systems whose published activation concentrations may overlap with reported human systemic exposure concentrations.

It does not currently demonstrate:

inadvertent activation in humans
a formal regulatory margin of exposure
clinical risk to engineered-cell recipients
that endogenous IAA causes wild-type AID activation in humans
that endoxifen produces the calculated CreERT2 margin
that sirolimus has the stated 2 nM functional threshold
a completed systematic scoping review
a general principle established across the field

Before any external use, the authors should re-extract every load-bearing number from primary figures or tables, document exact assay context, separate dosing scenarios, remove the endoxifen numerical claim, correct the Liberles citation, and reframe every ratio as exploratory rather than a clinical or regulatory safety conclusion.

Explain this to me I am confused

Reading File

Here is the simple version.

These documents are trying to answer:

“Could ordinary medicines, body chemicals, food chemicals, or cosmetics accidentally turn on an engineered biological switch?”

They compare:

How much of a chemical is needed to activate a switch in a lab experiment, with
How much of that chemical is found in a human body.

They divide one by the other.

Result below 1 means human exposure might be high enough to activate the switch.
Result above 1 means human exposure is lower than the reported lab activation concentration.

Why I said the documents are not yet trustworthy

The maths is usually fine. The problem is that the numbers being divided often do not truly match.

Think of it like this:

A car manual says a door opens with a particular key.
The report checks whether a key found in someone’s pocket could open it.
But sometimes it compares the wrong key, the wrong door, or a test done in a different building.

That is the main issue.

The three biggest problems

1. Some “activation thresholds” are not the right kind of number

A lab paper may say:

“At 10 µM, the switch was fully on.”

That does not mean:

“10 µM is the minimum concentration needed to begin activation.”

The switch could start activating at 0.1 µM, 1 µM, or something else entirely. If the report uses the “fully on” value as its threshold, it may make the switch look safer than it actually is.

This affects the trimethoprim and some AID calculations.

2. Some comparisons use different chemicals as though they were the same

The clearest error is endoxifen.

The report has a threshold for 4-OH-tamoxifen.
It compares that threshold against blood levels of endoxifen.

Both are related tamoxifen metabolites, but they are not identical chemicals. You cannot assume they activate the engineered receptor at the same concentration.

So the endoxifen number should not be used until a study gives an endoxifen-specific activation curve for that same switch.

3. Blood concentration is not necessarily the concentration at the engineered cells

A report may compare:

concentration in blood or plasma
with
concentration required in a dish of cultured cells.

But the engineered cells could be in a graft, tissue, tumour, or implant. The concentration reaching those cells could be lower, higher, shorter-lived, protein-bound, or otherwise different.

So a ratio below 1 does not prove that activation happens in a patient.

It only says:

“This deserves further testing.”

What is solid

A few things are genuinely supported:

The sirolimus blood-to-plasma conversion is correct.
The simple division arithmetic is mostly correct.
The original calculation for engineered AID systems was wrong because it compared a synthetic trigger's activation threshold with exposure to natural auxin. The documents correctly retract that.
A mouse study did show that topical commercial cosmetic products containing parabens could activate a designed implant switch in mice. That is real, but it does not prove the same event occurs in humans.

What should you believe about each main claim

Claim	What you should believe
“Doxycycline might activate Tet-On”	Possible enough to investigate, but not proven in patients.
“Trimethoprim exposure overlaps the degron activation range”	Uncertain, because the cited lab value appears to be a full-activation working dose, not a proper onset threshold.
“Sirolimus has a safe margin”	The blood-to-plasma conversion is right, but the activation threshold used is not yet properly verified.
“4-OH-tamoxifen may activate CreERT2 at human concentrations”	Plausible as a concern, but still depends on the particular construct and tissue.
“Endoxifen definitely has an even worse margin”	Not established. This is currently an invalid calculation.
“Natural auxin in humans activates wild-type AID”	Not proven. It is a hypothesis, not a demonstrated human effect.
“AID2 and super-sensitive AID are safe from natural auxin”	The original numerical comparison was invalid. Their environmental human-exposure margin is currently not calculable from these data.
“Cosmetics can activate a switch”	Demonstrated in a mouse implant experiment, not demonstrated as an accidental human risk.

What the project is, honestly

It is not yet a safety study and not a completed systematic review.

It is an early screening exercise that identifies possible overlap between:

published laboratory activation concentrations, and
published human exposure concentrations.

That can be useful for deciding what needs proper experiments next.

It cannot honestly claim:

accidental switch activation in humans
patient risk
regulatory safety margins
that any system is clinically safe or unsafe

One-sentence conclusion

The documents have found some potentially important warning signals, but they have not proven human activation or human harm, because key source values, chemical matching, and tissue-level exposure comparisons are still incomplete.

I understand all that I wanted to understand the trough etc the methods he used why it is wrong what methods he is using I just don’t get

Reading File

Finding Sources

Searching the Web

therapeutic drug monitoring trough concentration peak Cmax definition FDA pharmacokinetics

Searching the Web

Rapamune sirolimus whole blood trough concentration blood plasma ratio 36 18 label

He is using a screening calculation, not a direct experiment.

His basic method is:

[ \text{Ratio}=\frac{\text{concentration that activates the engineered switch in a lab}}{\text{concentration of the chemical measured in humans}} ]

He calls it SEM or MoE.

Ratio less than 1: the human concentration is at least as high as the lab activation concentration.
Ratio greater than 1: the human concentration is lower than the lab activation concentration.

The problem is not mainly the division. The problem is whether the two numbers being divided are truly comparable.

First: what “trough” means

Imagine someone takes a drug every day.

After a dose:

Drug level rises.
It reaches its highest level, called Cmax or the peak.
It falls as the body eliminates the drug.
Just before the next dose, it reaches its lowest level. This is the trough.

Drug concentration
      peak / Cmax
        /\
       /  \
      /    \
_____/      \_____  trough
 dose          next dose

So:

Cmax = highest blood concentration after a dose.
Trough = lowest blood concentration just before the next dose.
Average concentration = the average level over the dosing interval.
AUC = total exposure over time, represented by the area under the curve.

For sirolimus, clinicians commonly monitor a whole-blood trough, because it is a repeatable, clinically useful measure for adjusting doses. It is not necessarily the highest concentration in the body, and it is not a direct measurement of the concentration inside a graft or engineered cell. The Rapamune label gives whole-blood trough targets and notes that sirolimus partitions strongly into blood cells, with a blood-to-plasma ratio of about 36. FDA Rapamune label

Why trough was used in his sirolimus calculation

He found a published sirolimus trough range such as 4 to 20 ng/mL in whole blood.

Then he reasoned:

The engineered FKBP-FRB switch needs a certain concentration to activate.
A patient taking sirolimus has a measured whole-blood trough.
Compare the two to see whether routine treatment might activate the switch.

That is a sensible question to ask.

But he then noticed an important issue: the activation experiment is normally in a cell culture medium/plasma-like setting, while the clinical sirolimus value is in whole blood. These are not the same compartment.

Sirolimus is unusually concentrated inside blood cells, especially erythrocytes. So a whole-blood level of 20 ng/mL does not mean plasma concentration is 20 ng/mL.

His correction was:

[ \text{plasma concentration} \approx \frac{\text{whole-blood concentration}}{36} ]

So:

[ 4 \div 36 = 0.11 \text{ ng/mL} ]

[ 20 \div 36 = 0.56 \text{ ng/mL} ]

Then he converts ng/mL to nM because the cell experiment is reported in nM.

That conversion method is broadly reasonable.

Why the trough method is still not enough

Even after converting whole blood to plasma, he is still making this leap:

Blood trough
    ↓
estimated plasma trough
    ↓
assumed concentration around graft / engineered cells
    ↓
compared with a lab activation threshold

The weak step is the middle one.

A plasma trough is not automatically the amount of drug:

inside the engineered cell
at the graft site
free and able to bind the switch
present for long enough to cause activation
equivalent to the concentration used in the cell-culture experiment

So his calculation can say:

“Systemic sirolimus exposure may be in the same broad order of magnitude as a reported switch-activation concentration.”

It cannot say:

“A patient’s graft will definitely be activated by sirolimus.”

That would require experiments measuring activation in the relevant engineered cells under realistic exposure conditions.

The different methods he is mixing

He is using several types of numbers. This is why it feels confusing.

Type of number	Meaning	Example
Cmax	Highest blood level after dose	Doxycycline 1.5 to 7 µg/mL
Trough	Lowest level before next dose	Sirolimus 4 to 20 ng/mL whole blood
Average/steady-state level	Typical level after repeated dosing	Doxycycline average 482 ng/mL
EC50/DC50	Concentration producing 50% of the measured effect	300 nM gives half-maximal degradation
Working/saturating dose	A dose chosen to produce strong or complete effect	TMP 10 µM for full stabilization
Kd	Binding affinity, not necessarily functional activation	Sirolimus ternary-complex Kd
Food-residue level	Amount in food, not blood concentration	Agricultural auxin residue
Cell-culture threshold	Concentration tested in a dish	Tet-On activation begins above 10 ng/mL

He is trying to turn all of these into one common question:

“Could real human exposure reach a level that turns on the switch?”

But these values are not automatically interchangeable.

The main methodological errors, in plain English

Error 1: Comparing a peak to a threshold as though it were continuous exposure

For doxycycline he uses values up to 7,000 ng/mL, which can be a Cmax after a dose.

But Cmax is brief. It does not mean the body stays at 7,000 ng/mL all day.

If a switch needs sustained exposure for 24 hours, Cmax may exaggerate the risk. If a switch can be activated in minutes, Cmax may be relevant.

So the missing question is:

How long must the switch be exposed to activate?

A single maximum level cannot answer that.

Error 2: Mixing separate clinical scenarios in one range

For doxycycline, he combines:

low-dose steady-state levels, and
high single-dose peak levels

into one range: 482 to 7,000 ng/mL.

That produces a very wide ratio, but it blends patients receiving different doses and at different times after dosing.

Better method:

Clinical scenario	Human exposure value	Separate ratio
Low-dose steady-state	482 ng/mL average	Calculate separately
Low-dose Cmax	790 ng/mL	Calculate separately
Standard oral dose Cmax	1,500 to 7,000 ng/mL	Calculate separately

Then readers know exactly what each result means.

Error 3: Using “full activation” as though it means “first activation”

This is important for trimethoprim.

The documents use:

“10 µM TMP gives full or near-full stabilization.”

Then they treat 10 µM as the activation threshold.

But these are different:

0.1 µM: perhaps first detectable effect
1 µM: moderate effect
5 µM: strong effect
10 µM: full effect

If 10 µM is a dose selected to make the experiment work reliably, it is a working dose, not necessarily the lowest concentration that starts activation.

Using 10 µM can make the system appear to have more separation from human exposure than it actually has.

He partially realizes this and labels it an “upper bound,” meaning:

“The true activation threshold may be lower, so the apparent safety margin may be falsely reassuring.”

That correction is sensible, but it also means the numerical conclusion is still weak until the actual concentration-response curve is extracted.

Error 4: Confusing binding with activation

This was the original sirolimus mistake.

A Kd tells you how strongly molecules bind. It does not tell you exactly what concentration produces a biological response in a cell.

Example:

A key may fit into a lock at a very low concentration.
But the door may not open until many locks are occupied, other components are present, and enough time passes.

So comparing a binding Kd directly with blood drug concentration may be inappropriate if the real question is:

“Will the engineered cell turn on its gene program?”

For that, he should use a functional endpoint, such as transcriptional activation, degradation, or apoptosis.

That part of his logic is correct.

However, he then uses an inadequately verified “2 nM EC50” for sirolimus. The cited PNAS paper actually reports an EC50 below 10 nM for a specific non-toxic rapamycin analogue and mutated receptor system, not necessarily 2 nM for ordinary sirolimus in the exact system he is discussing. Original study

So he corrected the type of number but may still have the wrong specific number.

Error 5: Comparing two different chemicals

This is the endoxifen error.

He has:

4-OHT threshold: 6 nM
Endoxifen human level: 38 to 107 nM

Then he divides:

[ 6 \div 38 \text{ to } 107 ]

But that assumes:

4-OHT and endoxifen activate CreERT2 identically.

They are related, but not identical. Endoxifen can activate ERT2 fusions, yet it may have different potency and maximal activity. One study found endoxifen was a potent alternative but produced about half the activity of fresh 4-OHT in its tested system. Endoxifen and CreERT2 study

So the proper method is:

endoxifen concentration in humans
             ÷
endoxifen activation curve for that exact CreERT2 construct

Without the bottom number, he cannot validly calculate the ratio.

Error 6: Treating a lab dish concentration as equal to plasma concentration

This is the overall error.

A cell-culture experiment may use:

serum-free or serum-containing medium
a fixed exposure duration
different protein binding
different cell uptake
different cell type
much higher receptor expression than a patient graft
a different endpoint

A human plasma concentration may be total drug concentration, including drug bound to albumin and other proteins.

The cells often respond to the free concentration at the receptor, not simply the total concentration reported by the laboratory.

So a better comparison needs to match:

same chemical
same active form
same unit
same compartment
same exposure duration
same biological endpoint
same or relevant cell system

His calculations often match only the chemical name and units.

What he should have done instead

A scientifically cleaner process would be:

Step 1: Choose one real clinical scenario

For example:

“A renal-transplant recipient taking sirolimus, measured immediately before the next 24-hour dose.”

Not “all sirolimus exposures from 4 to 20 ng/mL.”

Step 2: Define the clinical concentration correctly

Is it whole blood, plasma, free plasma, tissue, or intracellular?
Is it Cmax, trough, average, or AUC?
Is it standard dose or high dose?

Step 3: Find a functional concentration-response curve

Not a Kd.
Not simply a laboratory working dose.

Preferably identify:

lowest observed functional effect
EC10 or EC20, if available
EC50
full-effect concentration
duration required for response

Step 4: Match the experimental and clinical conditions

The best experiment would expose the actual engineered therapeutic cells to a concentration-time profile similar to human plasma or tissue exposure.

For example:

Expose engineered cells to:
0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM sirolimus
for:
1 hour, 6 hours, 24 hours, repeated daily
then measure:
gene activation / degradation / apoptosis

That would answer the real question.

Step 5: State the result cautiously

Then say:

“At clinically plausible free plasma concentrations, this construct did or did not show measurable activation under these defined experimental conditions.”

That is much stronger than a simple ratio based on unrelated studies.

The simplest way to understand his work

He is doing this:

“I found a number from a human drug study and a number from a switch paper. I divided them to see if they overlap.”

That is a reasonable first-pass warning screen.

But he is sometimes comparing:

the lowest human level with the highest lab level
a peak with a sustained lab exposure
whole blood with culture medium
one chemical with another chemical
binding with function
a full-effect dose with an onset-of-effect dose

That is why the method may generate useful questions, but cannot provide final answers about patient risk or accidental activation.

But in this multimillion dollar industry it still hasn’t gone to human trails and I can’t do it as a second year mbbs in osmania

You are right. You cannot, and should not, be expected to run human trials as a second-year MBBS student.

That is not the standard your project needs to meet.

The issue is not:

“You have not proven this in humans, therefore the project is bad.”

The issue is only:

“Do not write that you proved it happens in humans.”

Your project can still be good if you frame it correctly.

What your project can honestly be

Not:

A study proving inadvertent activation of engineered switches in humans.

But:

A literature-based risk-screening and evidence-mapping project that identifies engineered control systems where reported human systemic exposures may overlap with reported in-vitro functional activation concentrations.

That is a legitimate student-level research question.

Your contribution is not to do the human trial. Your contribution is to identify which systems deserve the expensive follow-up experiment.

The industry analogy

Drug and synthetic-biology companies cannot test every possible interaction in humans first.

They use stages:

Literature and theoretical screening
Could a drug or common chemical plausibly overlap with the switch's activation range?
Cell-culture testing
Expose relevant engineered cells to clinically realistic concentrations and times.
Animal studies, if appropriate.
Human trials, only with ethics approval, funding, manufacturing controls, safety monitoring, and a serious clinical reason.

Your work belongs at stage 1.

That is useful because it may tell a future lab:

Do not choose doxycycline if the intended patient population will frequently receive doxycycline.
Test tamoxifen metabolites before using CreERT2 in patients who may receive tamoxifen.
Prefer a synthetic ligand-receptor pair, such as AID2, when avoiding background natural-ligand activation matters.
Build a formal drug-interaction screen into the design of engineered-cell therapy.

The correct scientific claim

You can say:

“This review does not establish inadvertent activation in humans. It identifies systems in which published human exposure estimates are within, or exceed, published in-vitro functional concentration ranges. These systems should be prioritized for construct-specific pharmacokinetic-pharmacodynamic testing before clinical translation.”

That is strong, accurate, and fair.

What your method needs to do

You do not need perfect human data. You need to show that you handled uncertainty properly.

For each system, make a table with:

Item	What you report
Trigger	Exact chemical, for example doxycycline
Engineered system	Tet-On, CreERT2, FKBP-FRB, AID2, etc.
Functional endpoint	Gene expression, degradation, apoptosis
Lab value	Lowest observed effect, EC50, or working dose
Human exposure	Cmax, trough, or average level, clearly labelled
Compartment	Whole blood, plasma, free plasma, tissue, unknown
Comparison quality	Direct, approximate, or not comparable
Interpretation	“Possible overlap,” “no inference,” or “not calculable”
Next experiment	What a specialist lab would need to test

This turns the limitations into part of the result.

Your supervisor should not expect this

You are not claiming:

“This will activate in people.”
“This will harm patients.”
“This system is unsafe.”
“This is a regulatory safety margin.”

You are claiming:

“There is enough published numerical overlap to justify targeted testing.”
“Some comparisons cannot be made because the ligand, compartment, or endpoint differs.”
“The literature often reports activation in ways that make clinical cross-comparison difficult.”

That last point may actually be your best finding.

A clean aim for your report

To map published functional activation concentrations for engineered chemical-control systems against reported human exposure concentrations of their triggers or related compounds, identify potential exposure-overlap signals, and define the evidence gaps that prevent clinical-risk conclusions.

A clean conclusion

“The evidence does not permit inference of inadvertent activation in humans. However, several systems show numerical overlap between reported human systemic concentrations and in-vitro functional response ranges. Because these comparisons are affected by ligand specificity, pharmacokinetic compartment, protein binding, exposure duration, and construct-specific biology, the findings should be interpreted as prioritisation signals for preclinical testing rather than estimates of clinical risk.”

That is a rigorous second-year MBBS project. It is realistic, honest, and potentially valuable.

Is this useful research at all in the globe

Reading File

Searching PubMed

synthetic biology inducible gene switch clinical translation review

Searching PubMed

engineered cell therapy safety switch inducible review

Finding Sources

Searching the Web

2025 review chemically induced gene switches cell therapy safety synthetic biology clinical translation

Yes, the question is globally useful. But the current work is useful as a structured evidence map and preclinical risk-screen, not as proof of patient risk.

Why the question matters worldwide

Engineered cells and gene circuits are increasingly designed to be turned on or off by small molecules. This includes CAR-T cells, implanted designer cells, gene therapies, and research tools.

For every chemical switch, developers must ask:

Does the trigger reach the right concentration in the body?
Could a patient’s regular medication accidentally activate or interfere with it?
Does the trigger have harmful effects of its own?
Is the trigger truly orthogonal, meaning it does not interact with normal human biology or common environmental chemicals?

These are real translation problems, not imaginary ones. Recent reviews of synthetic gene circuits explicitly focus on safety, controllability, pharmacokinetics, orthogonality, and clinical translation. For example, a 2024 review of molecularly responsive circuits discusses how these switches may control therapeutic cells, while a 2024 CAR-T safety-switch review addresses spatiotemporal control and safety. A 2023 paper developing a simeprevir-controlled switch specifically says trigger pharmacokinetics, safety, orthogonality, and protein-component immunogenicity must be considered for clinical use, and notes that rapamycin is problematic because it has natural mammalian targets and immunosuppressive effects. Simeprevir switch study

So your central question is valid:

Before using a chemical-inducible switch in a patient, has anyone systematically checked whether realistic human exposure to the trigger, related drugs, metabolites, diet-derived molecules, or environmental chemicals could produce unwanted activation?

That is useful globally.

What is already known globally

The world already knows, in a general sense, that trigger selection matters.

Examples:

Rapamycin/sirolimus is a poor ideal trigger for many therapeutic switches because it is an active immunosuppressive drug and acts on the natural mTOR pathway.
Doxycycline/Tet-On is convenient in laboratories, but doxycycline is a common antibiotic with real human exposure and microbiome effects.
Tamoxifen/CreERT2 is useful in experimental models, but tamoxifen and metabolites are pharmacologically active and clinically used.
Synthetic-ligand systems, such as bump-and-hole pairs, are developed partly to improve specificity and avoid background activity.
Safety switches are already an important issue in adoptive cell therapy, including CAR-T therapy. See the 2022 safety-switch review.

Therefore, the raw idea is not completely new worldwide.

Where your project can add something

The potentially useful gap is this:

The field discusses orthogonality, trigger pharmacology, and safety separately, but may not consistently present a transparent, construct-by-construct map comparing functional activation data with actual human pharmacokinetic exposure data.

In simpler terms, researchers may say:

“Use an orthogonal trigger.”

But they may not always show:

“Here is the exact published human blood exposure, here is the exact functional activation curve, here is whether the comparison is valid, and here is what experiment is needed before clinical use.”

That can be a worthwhile contribution if done carefully.

Your strongest possible output is not “we found unsafe switches.”

It is:

“We created a reproducible way to identify which switch-trigger systems need focused pharmacokinetic-pharmacodynamic testing before clinical translation.”

That can help a lab choose between triggers during early design.

Is it useful enough for publication?

As it currently stands

Probably not for a strong international journal, because:

the data sources are not yet fully verified from primary figures;
several comparisons are incompatible;
the terminology overstates what the calculation can establish;
it covers too many heterogeneous systems;
it does not yet have a reproducible systematic-review method.

It could still be a strong MBBS research project, poster, student conference abstract, or local journal paper after revision.

If rebuilt properly

It could become genuinely useful internationally as a focused scoping review or methods paper, especially if it asks one narrow question, for example:

“How are pharmacokinetics, exposure duration, free drug concentration, off-target pharmacology, and endogenous-ligand exposure assessed when selecting small-molecule triggers for clinically intended engineered-cell therapies?”

Or:

“A framework for pharmacokinetic and environmental-orthogonality assessment of chemical control systems intended for engineered-cell therapies.”

That is closer to the real global translational problem.

What would make it globally credible

Do not try to prove human harm. Instead, make a high-quality decision framework.

For each switch, report:

Exact trigger and exact receptor/switch
Whether the trigger has normal human biological activity
Functional activation curve, not just a binding Kd or a laboratory working dose
Exposure duration required for activation
Human pharmacokinetics, clearly separated into Cmax, trough, average concentration, and free concentration where available
Compartment: whole blood, plasma, tissue, intracellular, or unknown
Ligand match: same chemical, metabolite, analogue, or unrelated chemical
Evidence grade
Conclusion category:
- direct concern requiring testing
- possible overlap but not comparable
- no usable comparison
- evidence gap
Next experiment required

That is useful to scientists anywhere, because it tells them what must be checked before choosing a trigger.

The honest verdict

The idea: useful internationally.
The scientific problem: real and current.
The present calculations: too weak to make clinical claims.
Your realistic contribution as an MBBS student: valuable, if you make it a careful evidence map and preclinical prioritisation framework.
The main finding you may be able to defend: published studies often do not report activation data and human exposure data in a form that allows a valid clinical-translation comparison.

That is not a small finding. It is exactly the kind of gap that can guide better design of future engineered-cell therapies.

But this is not in any website I searched and also it is new and and I need to know if it might become better for icmr

Searching PubMed

small molecule inducer pharmacokinetics orthogonality engineered cell therapy

Searching PubMed

chemical induced dimerization pharmacokinetics clinical translation safety

Searching PubMed

inducible gene switch drug interactions engineered cells

Searching the Web

"pharmacokinetic orthogonality" "gene switch" OR "engineered cell"

Searching the Web

ICMR STS 2026 guidelines undergraduate research proposal selection criteria innovation feasibility literature review

Finding Sources

Yes, it might become better for ICMR, but only if you make the novelty precise and keep the project feasible.

First: why you cannot find this exact idea online

You may not find your exact phrase because your project is combining things that researchers usually discuss separately:

Gene switches / engineered-cell control systems
Pharmacokinetics, such as Cmax, trough, half-life, plasma level
Orthogonality, meaning whether a trigger interferes with normal human biology or other chemicals
Clinical translation, meaning whether a laboratory switch is suitable for eventual use in patients

The field already knows all four topics matter. For example, the 2023 simeprevir-inducible switch paper specifically says a trigger for cell/gene therapy should be selected based on its safety, pharmacokinetic profile, and orthogonality. It also explains why rapamycin can be problematic: it has natural mammalian targets and immunosuppressive effects. Simeprevir-switch paper

So do not claim:

“Nobody has ever considered pharmacokinetics or orthogonality in gene switches.”

That would be false.

But you may be able to claim, after a proper search:

“We did not identify a published, reproducible evidence-mapping framework that systematically evaluates whether each chemical gene switch has sufficient matched evidence across functional activation, human pharmacokinetics, compartment, exposure duration, ligand specificity, and endogenous/environmental cross-reactivity.”

That is a defensible potential gap.

Your novelty is not inventing gene switches. It is creating a transparent clinical-translation checklist for choosing their chemical triggers.

Is that good for ICMR?

Potentially yes, but not in its current form

ICMR-type undergraduate proposals need four things:

A clear health relevance
A focused question
A method you can finish
An output that is useful even without a laboratory or clinical trial

Your present project is too broad and sometimes sounds like it is trying to prove patient risk. That makes it vulnerable to rejection because reviewers can ask:

“Where is the human evidence?”
“Why is an MBBS student doing advanced synthetic biology?”
“What exactly is the study outcome?”
“Are you calling a literature review a safety study?”

You can solve that by making it a methods and evidence-mapping project, not a clinical risk study.

The version that could work

Suggested title

Clinical translational readiness of small-molecule gene switches: a scoping review of functional activation evidence, human pharmacokinetics, and orthogonality

Or, shorter:

Can chemical gene switches be clinically translated safely? An evidence map of trigger pharmacokinetics and functional activation data

Avoid words like:

exposome-orthogonality
safety margin
inadvertent activation in humans
audit
proof of risk

Those terms either sound invented, too broad, or claim more than your data can show.

Your real research question

Among published small-molecule-controlled mammalian gene switches intended for therapeutic or translational use, how often do published studies provide enough matched evidence to compare functional activation with clinically relevant human exposure?

That is a real question.

It does not require you to test patients.

It does not claim a switch is unsafe.

It asks whether the published evidence is enough for responsible clinical translation.

What you would actually do

For each selected switch system, extract the following:

Domain	Question
Switch	What exact engineered receptor or control system is used?
Trigger	What exact chemical activates it?
Functional result	Is activation measured as gene expression, degradation, apoptosis, etc.?
Activation data	Is there a dose-response curve, EC50, EC10, lowest effective concentration, or only a working dose?
Exposure time	Minutes, hours, days, or unspecified?
Human PK	Is there human Cmax, trough, free plasma concentration, or only a dose?
Compartment match	Are both values plasma, whole blood, tissue, intracellular, or not comparable?
Ligand match	Is the exact same chemical being compared, or a metabolite/analogue?
Endogenous cross-reactivity	Could body chemicals activate the switch?
Off-target pharmacology	Does the trigger itself have important human effects?
Overall status	Directly comparable, approximate only, or not calculable?

Your main result would be a clinical-translation evidence matrix.

That matrix is the research output.

A good primary outcome

Do not make your main outcome “MoE below 1.”

Make your main outcome:

The proportion of published chemical-switch systems with a clinically interpretable activation-exposure comparison.

Define a comparison as “clinically interpretable” only if all these are present:

Same chemical, not a related metabolite or analogue
Functional activation endpoint, not binding Kd alone
Dose-response information, not merely a working concentration
Defined exposure duration
Human pharmacokinetic value
Stated compartment or a valid conversion
Clear limitation if graft-site concentration is unknown

Then your conclusions will be strong even if you find that most systems cannot be compared.

For example:

“Only 2 of 12 systems reported enough information to make an approximate functional activation-to-human exposure comparison. Common missing variables were free concentration, duration of exposure, tissue distribution, and construct-specific dose-response data.”

That is useful.

Why this is more credible than the present MoE table

The present table tries to answer:

“Could this activate in a patient?”

Your revised project asks:

“Does the published literature provide enough evidence to answer that question responsibly?”

The second question is fully answerable by you.

And it can reveal a meaningful research gap.

Example

Bad conclusion

“Endoxifen will activate CreERT2 in humans because its level is above 6 nM.”

This is invalid because 6 nM was a 4-OHT threshold, not an endoxifen threshold.

Good evidence-map conclusion

“Human endoxifen concentrations are reported, and endoxifen can activate ERT2 fusions in experimental studies; however, no matched endoxifen-specific concentration-response threshold for the relevant CreERT2 construct was identified. A quantitative exposure-activation comparison is therefore not currently interpretable.”

That is rigorous and useful.

What makes it novel enough

You should not say “this has never been done” merely because it does not appear in a Google search.

Novelty needs a documented search.

You can say:

“Existing reviews discuss molecular switch design, safety, and clinical translation. However, they do not consistently use a structured system-by-system framework to assess the compatibility of functional activation data with human PK data and real-world ligand exposure.”

That is likely defensible. The existing literature clearly recognises the problem. Reviews cover molecularly responsive gene circuits and their translational limitations, while switch-development papers explicitly consider pharmacokinetics and orthogonality. See the 2024 review of responsive circuits, the 2021 review of implantable-cell switches, and the 2020 review of small-molecule transcriptional control.

Your contribution would be to turn those general principles into a reproducible appraisal tool.

Is it feasible for a second-year MBBS student?

Yes, if you narrow it.

Do not examine every switch ever made. Do not try to cover all synthetic biology.

Choose one of these scopes:

Best option

Small-molecule-controlled mammalian gene switches with a stated therapeutic, implanted-cell, gene-therapy, or CAR-T application.

Then include perhaps 10 to 20 eligible systems, depending on the search yield.

Even more feasible

Three commonly used trigger families:

tetracyclines, such as doxycycline/Tet-On
tamoxifen metabolites/CreERT2
chemical-inducer-of-dimerization systems, such as rapamycin-based switches

This is smaller, clearer, and easier to finish.

Do not include agricultural pesticides, every natural metabolite, food residues, unrelated synthetic analogues, and all possible environmental chemicals in the first ICMR project. That makes the project look unmanageable.

The one improvement that changes the project most

Replace the central calculation with a translation-readiness score.

For example, score each system from 0 to 7:

Criterion	Score
Functional dose-response is reported	1
Lowest effect or EC50 is reported	1
Activation exposure duration is reported	1
Exact trigger has human PK data	1
Same biological compartment is compared	1
Free versus total concentration is addressed	1
Endogenous or environmental cross-reactivity is assessed	1

Interpretation:

0 to 2: not clinically interpretable
3 to 5: preliminary, important gaps
6 to 7: reasonably translationally characterised

This is much safer than pretending every row has a formal safety margin.

You can still include ratios as a secondary exploratory result, only when the source values genuinely match.

My frank view on ICMR suitability

It can be good for ICMR if:

your guide is supportive;
the protocol is written like a proper scoping review;
the question stays focused;
you do not claim clinical risk;
you give a usable output, such as a reporting checklist or decision framework;
you clearly state this is preclinical translational evidence mapping.

It may be rejected if:

it remains too broad;
the writing sounds like an AI-generated grand theory;
it claims “first in the world” without proving it;
it uses invented terminology;
it calls basic ratios “regulatory MoE”;
it tries to cover every inducible system, drug, metabolite, food chemical, and environmental exposure.

The honest positioning sentence

Use this:

“This study does not estimate clinical risk or demonstrate unintended activation in humans. It maps whether published evidence on small-molecule gene switches is sufficient to support clinically meaningful activation-exposure assessment and identifies the specific pharmacokinetic, pharmacodynamic, and orthogonality data required before clinical translation.”

That is not weak. It is exactly proportionate to what a literature-based student project can establish.

Rewrite this as an ICMR-ready research proposal

Reading File

Searching the Web

site:icmr.gov.in STS 2026 guidelines proposal research plan undergraduate short term studentship

Searching PubMed

small molecule inducible transcriptional control mammalian cells

Searching PubMed

engineered cell therapy small molecule gene switch clinical translation

Browsing Directory

/tmp/workspace

Running Command

mkdir -p "/tmp/workspace/icmr-sts-gene-switch-proposal/output" "/tmp/workspace/icmr-sts-gene-switch-proposal/src" && python3 - <<'PY' from docx import Document from docx.shared import Inches, Pt from docx.enum.text import WD_ALIGN_PARAGRAPH from docx.enum.table import WD_TABLE_ALIGNMENT, WD_CELL_VERTICAL_ALIGNMENT from docx.oxml import OxmlElement from docx.oxml.ns import qn from pathlib import Path out=Path('/tmp/workspace/icmr-sts-gene-switch-proposal/output/ICMR_STS_Proposal_Gene_Switch_Translation_Readiness.docx') doc=Document() sec=doc.sections[0] sec.top_margin=Inches(.7); sec.bottom_margin=Inches(.7); sec.left_margin=Inches(.78); sec.right_margin=Inches(.78) styles=doc.styles styles['Normal'].font.name='Arial'; styles['Normal']._element.rPr.rFonts.set(qn('w:eastAsia'),'Arial'); styles['Normal'].font.size=Pt(10) styles['Normal'].paragraph_format.space_after=Pt(5) for nm,size in [('Title',15),('Heading 1',12),('Heading 2',10.5)]: s=styles[nm]; s.font.name='Arial'; s._element.rPr.rFonts.set(qn('w:eastAsia'),'Arial'); s.font.size=Pt(size); s.font.bold=True s.paragraph_format.space_before=Pt(9); s.paragraph_format.space_after=Pt(4) def shade(cell, fill): tcPr=cell._tc.get_or_add_tcPr(); shd=OxmlElement('w:shd'); shd.set(qn('w:fill'),fill); tcPr.append(shd) def set_cell(cell,text,bold=False): cell.text=''; p=cell.paragraphs[0]; r=p.add_run(text); r.bold=bold; r.font.name='Arial'; r.font.size=Pt(9); cell.vertical_alignment=WD_CELL_VERTICAL_ALIGNMENT.CENTER def table(rows, widths=None, header=True): t=doc.add_table(rows=0, cols=len(rows[0])); t.style='Table Grid'; t.alignment=WD_TABLE_ALIGNMENT.CENTER for i,row in enumerate(rows): cells=t.add_row().cells for j,val in enumerate(row): set_cell(cells[j],str(val),bold=(header and i==0)) if header and i==0: shade(cells[j],'D9EAF7') if widths: cells[j].width=Inches(widths[j]) return t def p(text='', boldlead=None): par=doc.add_paragraph() if boldlead and text.startswith(boldlead): par.add_run(boldlead).bold=True; par.add_run(text[len(boldlead):]) else: par.add_run(text) return par def bullets(items): for x in items: para=doc.add_paragraph(style='List Bullet'); para.add_run(x) t=doc.add_paragraph(); t.alignment=WD_ALIGN_PARAGRAPH.CENTER r=t.add_run('ICMR SHORT-TERM STUDENTSHIP (STS) RESEARCH PROPOSAL');r.bold=True;r.font.size=Pt(12) t=doc.add_paragraph();t.alignment=WD_ALIGN_PARAGRAPH.CENTER r=t.add_run('Clinical Translation Readiness of Small-Molecule-Controlled Mammalian Gene Switches: A Scoping Review of Functional Activation, Human Pharmacokinetics and Orthogonality Evidence');r.bold=True;r.font.size=Pt(15) sub=doc.add_paragraph(); sub.alignment=WD_ALIGN_PARAGRAPH.CENTER; sub.add_run('Protocol for a literature-based evidence-mapping study').italic=True table([ ['Student investigator','[Name], Second-year MBBS, Osmania Medical College'], ['Guide / Co-guide','[Name, Department and designation]'], ['Institution','Osmania Medical College, Hyderabad, Telangana'], ['Proposed duration','8 weeks after approval'], ['Study design','Scoping review with structured evidence mapping'], ['Human participants / specimens','None'] ], widths=[1.8,4.9], header=False) p('1. Background and rationale') p('Small-molecule-responsive gene switches are engineered systems that permit external control of gene expression, protein degradation, cell survival, or immune-cell activity. They are being developed for cell and gene therapy, including CAR-T-cell and implantable-cell applications. Their clinical utility depends not only on whether a switch works in cultured cells, but also on whether its trigger has an acceptable human safety profile, pharmacokinetic profile, and degree of biological orthogonality.') p('Existing reviews describe small-molecule regulators and translational challenges of gene switches. However, reported activation data are heterogeneous: studies may report a binding affinity, a single working concentration, or a functional concentration-response curve. Human exposure data may be reported as plasma Cmax, whole-blood trough concentration, average steady-state concentration, or no human pharmacokinetic value. These values are often not directly comparable. A transparent evidence map is needed to identify whether a published switch has enough matched information for a clinically interpretable exposure-activation assessment.') p('This study will not estimate clinical risk, claim accidental activation in humans, or recommend clinical use of a specific switch. Its purpose is to map the completeness and comparability of the published evidence needed before such questions can be tested experimentally.') p('2. Research question') p('Among small-molecule-controlled mammalian gene switches proposed for therapeutic, implantable-cell, gene-therapy, or engineered immune-cell applications, how often does the published literature provide sufficient matched functional, pharmacokinetic, and orthogonality evidence for a clinically interpretable activation-exposure assessment?') p('3. Aim') p('To map the clinical translation readiness of small-molecule-controlled mammalian gene switches by assessing the completeness and comparability of published functional activation, human pharmacokinetic, and orthogonality evidence.') p('4. Objectives') bullets([ 'To identify published small-molecule-controlled mammalian gene switches with a stated therapeutic, implantable-cell, gene-therapy, or engineered immune-cell application.', 'To extract the exact trigger, switch construct, functional endpoint, concentration-response evidence, and exposure duration reported for each eligible system.', 'To extract human pharmacokinetic evidence for the exact trigger, including concentration metric, compartment, dosing context, and source.', 'To assess whether functional and human exposure values are directly comparable, approximately comparable, or not quantitatively comparable.', 'To classify each system using a pre-specified Translation Readiness Evidence Score and identify common evidence gaps.' ]) p('5. Methods') p('5.1 Study design and reporting') p('Scoping review. The protocol will be finalized and dated before screening and data extraction. Reporting will follow PRISMA-ScR where applicable. The study will use only published literature and publicly available drug-label or regulatory pharmacokinetic information.') p('5.2 Eligibility criteria') table([ ['Domain','Inclusion criteria','Exclusion criteria'], ['System','Mammalian-cell gene switches or chemically induced protein-control systems activated by a small molecule.','Microbial-only, plant-only, or purely in vitro biochemical systems without mammalian-cell evidence.'], ['Application','Paper states or demonstrates a therapeutic, cell-therapy, gene-therapy, implantable-cell, or engineered immune-cell application.','Systems developed solely as routine laboratory tools with no stated translational application.'], ['Evidence type','Original research reports and their primary supplementary material; human drug labels/regulatory documents used for PK.','Narrative reviews as primary data sources, editorials, protocols without results, conference abstracts with insufficient data.'], ['Language/date','English; database inception to search date.','Non-English articles where a reliable full translation cannot be obtained.'] ],widths=[1.15,3.0,2.55]) p('A system will be counted once per unique switch-trigger pair. Distinct triggers used with the same switch will be recorded separately. Reviews will be used only for citation chasing, not for extraction of primary functional values.') p('5.3 Information sources and search strategy') p('PubMed, Scopus or Web of Science if institutional access is available, and Google Scholar will be searched from inception to the final search date. Reference lists of eligible studies and recent reviews will be screened. Human PK will be sourced preferentially from regulatory product labels, then original human PK studies, and lastly high-quality reviews if primary sources are unavailable.') p('Core PubMed search: ("gene switch" OR "inducible gene" OR "chemical inducible" OR "small molecule inducible" OR "chemically induced dimerization" OR "drug-controlled") AND (mammalian OR "T cell" OR "cell therapy" OR "gene therapy" OR therapeutic). The final full search strings, date, and record counts will be reported as an appendix.') p('5.4 Screening and selection') p('Records will be deduplicated in Zotero. Titles and abstracts will be screened against the eligibility criteria, followed by full-text screening. The student investigator will conduct screening; the guide will independently check a random 20% sample of titles/abstracts and all full-text exclusions with uncertain eligibility. Disagreements will be resolved by discussion. A PRISMA-style flow diagram will be prepared.') p('5.5 Data extraction') p('A pilot-tested extraction sheet will be used. The guide will verify all extracted values used in the final evidence matrix and a random 20% of remaining fields. Exact page, figure, table, or supplementary-figure locations will be recorded for every numerical functional value.') table([ ['Field group','Data to be extracted'], ['Switch identity','Switch name; receptor/protein components; host cell; stated intended application.'], ['Trigger identity','Exact chemical; active metabolite/analogue status; known endogenous ligand relation.'], ['Functional evidence','Endpoint such as gene expression, degradation, apoptosis, or cell function; concentration-response curve availability; lowest observed functional effect, EC50/EC10 where reported, and working concentration; exposure duration.'], ['Human PK','Exact trigger; dose/regimen; Cmax, trough, average concentration, AUC where reported; total/free concentration; compartment; source.'], ['Comparability','Ligand match; unit conversion; compartment match; time/exposure match; explicit limitations.'], ['Orthogonality / safety','Known endogenous activity, established pharmacological target, clinically relevant adverse effects, and reported endogenous/environmental cross-reactivity.'] ],widths=[1.55,5.15]) p('5.6 Pre-specified comparability categories') table([ ['Category','Definition'], ['Directly comparable','Exact trigger is used in both sources; functional endpoint is reported in mammalian cells; exposure duration is reported; human PK is available; and compartment is the same or a published conversion is available.'], ['Approximate comparison only','Exact trigger and functional evidence are available, but one or more major limitations remain, such as total rather than free concentration, plasma used as a proxy for target tissue, or unmatched exposure duration.'], ['Not quantitatively comparable','Different ligand/metabolite/analogue is used; only binding Kd or a working dose is available; no human PK exists for the trigger; or compartments/units cannot be reconciled.'] ],widths=[1.7,5.0]) p('No numerical activation-to-exposure ratio will be calculated for the “not quantitatively comparable” category. For directly comparable or approximate cases, any exploratory ratio will be reported only with its endpoint type and limitations. It will not be called a regulatory Margin of Exposure and will not be interpreted as clinical risk.') p('5.7 Translation Readiness Evidence Score') p('Each switch-trigger pair will receive one point for each item below, maximum 7. This is an evidence-completeness tool, not a validated clinical safety score.') table([ ['Criterion','Score'], ['Functional concentration-response data are reported.','1'], ['A functional onset measure or ECx is reported, rather than only a binding Kd or working dose.','1'], ['Functional exposure duration is reported.','1'], ['Human pharmacokinetic data exist for the exact trigger.','1'], ['Human exposure compartment is specified.','1'], ['Functional and human compartments are matched or a published conversion is provided.','1'], ['Endogenous/off-target pharmacology or cross-reactivity is assessed or explicitly discussed.','1'] ],widths=[5.8,.9]) p('Score interpretation: 0 to 2, insufficient evidence for quantitative comparison; 3 to 5, preliminary evidence with material gaps; 6 to 7, comparatively well characterized for preclinical translation. The score is descriptive and will not be used to rank patient safety.') p('5.8 Outcomes and analysis plan') p('Primary outcome: proportion of eligible switch-trigger pairs classified as directly comparable, approximate comparison only, or not quantitatively comparable.') p('Secondary outcomes: median Translation Readiness Evidence Score with interquartile range; proportion reporting concentration-response data, exposure duration, exact-trigger human PK, compartment information, and endogenous/off-target assessment; and frequency of each missing-data domain.') p('Data will be summarized with counts and percentages. No meta-analysis will be performed because switch architectures, triggers, endpoints, assay conditions, and PK metrics are expected to be heterogeneous. Results will be presented as an evidence matrix, bar charts of missing-data domains, and a narrative synthesis.') p('6. Sample size') p('No patient or laboratory sample is involved. The sample will be all eligible published switch-trigger pairs identified by the predefined search. If more than 30 eligible pairs are identified, the first 30 consecutively eligible pairs after screening will be included only if required to maintain feasibility; this contingency will be reported transparently. The preferred plan is to include all eligible records.') p('7. Ethical considerations') p('This study uses published literature and publicly accessible regulatory documents only. It involves no human participants, biological samples, intervention, or identifiable personal data. An Institutional Ethics Committee exemption or written determination of exemption will be sought according to local institutional policy before commencement. Data extraction will preserve source attribution and the final report will follow ICMR principles on research integrity, plagiarism, and responsible reporting.') p('8. Expected outcomes and relevance') p('The study will produce: (i) a structured evidence map of small-molecule gene switches with translational applications; (ii) a checklist of minimum information needed for clinically interpretable activation-exposure assessment; and (iii) a prioritized list of evidence gaps requiring construct-specific preclinical testing. This is relevant to emerging cell and gene therapies because external chemical control must be assessed alongside pharmacology, tissue exposure, and possible interaction with endogenous or commonly administered molecules.') p('The study will not identify safe or unsafe products. It will identify where published evidence is sufficient or insufficient to support rational preclinical follow-up. This is feasible without laboratory experimentation and is appropriate for an undergraduate research project.') p('9. Timeline') table([ ['Week','Activity'], ['1','Finalize protocol, obtain guide approval and IEC exemption/determination; pilot search and extraction form.'], ['2','Run database searches, deduplicate, title/abstract screening.'], ['3-4','Full-text screening, citation chasing, and PK-source identification.'], ['5-6','Data extraction, guide verification, and evidence classification.'], ['7','Analysis, figures, PRISMA flow diagram, and draft report.'], ['8','Revision with guide, final report, and dissemination plan.'] ],widths=[.7,6.0]) p('10. Feasibility and limitations') p('The project requires access to bibliographic databases, reference-management software, spreadsheet software, and guide supervision. It does not require laboratory equipment, patient recruitment, drug administration, or funding for assays. Anticipated limitations include publication bias, incomplete reporting, construct-specific heterogeneity, and inability to infer tissue-level exposure or clinical activation from published systemic PK. These limitations are the subject of the evidence map rather than reasons to make clinical claims.') p('11. Dissemination') p('Results will be submitted as the ICMR STS report and may be presented as a poster at a student research forum after guide and institutional approval. A manuscript will be considered only after complete verification of all primary-source numerical values and according to authorship and institutional policies.') p('12. Selected references') refs=[ '1. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467-473. doi:10.7326/M18-0850.', '2. Siddiqui MM, Tous C, Wong WW. Small molecule-inducible gene regulatory systems in mammalian cells: progress and design principles. Curr Opin Biotechnol. 2022;78:102823. doi:10.1016/j.copbio.2022.102823.', '3. Mansouri M, Fussenegger M. Small-Molecule Regulators for Gene Switches to Program Mammalian Cell Behaviour. ChemBioChem. 2024;25:e202300717. doi:10.1002/cbic.202300717.', '4. Madderson OO, Teixeira AP, Fussenegger M. Emerging mammalian gene switches for controlling implantable cell therapies. Curr Opin Chem Biol. 2021;64:101-110. doi:10.1016/j.cbpa.2021.05.012.', '5. Galvan S, Teixeira AP, Fussenegger M. Enhancing cell-based therapies with synthetic gene circuits responsive to molecular stimuli. Biotechnol Bioeng. 2024;121:2987-3000. doi:10.1002/bit.28770.', '6. Chin SE, Schindler C, Vinall L, et al. A simeprevir-inducible molecular switch for the control of cell and gene therapies. Nat Commun. 2023;14:7840. doi:10.1038/s41467-023-43484-9.', '7. Zheng Y, Nandakumar KS, Cheng K. Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. J Med Chem. 2021;64:11919-11941. doi:10.1021/acs.jmedchem.0c02054.', '8. ICMR. Short-Term Studentship (STS). Available from: https://www.icmr.gov.in/short-term-studentship-sts. Accessed 21 September 2026.' ] for ref in refs: para=doc.add_paragraph(style='List Number');para.add_run(ref) # footer footer=sec.footer.paragraphs[0]; footer.alignment=WD_ALIGN_PARAGRAPH.CENTER; footer.add_run('ICMR STS proposal draft | Replace bracketed fields and obtain guide/IEC approval before submission').font.size=Pt(8) doc.save(out) print(out) PY python3 - <<'PY' from docx import Document p='/tmp/workspace/icmr-sts-gene-switch-proposal/output/ICMR_STS_Proposal_Gene_Switch_Translation_Readiness.docx' d=Document(p) print('paras',len(d.paragraphs),'tables',len(d.tables)) print(d.paragraphs[1].text) print(d.paragraphs[-2].text) PY

I rewrote it into a focused, feasible ICMR STS-style proposal.

The revised proposal does not claim to prove accidental activation or patient risk. It asks a defensible literature-based question:

Do published small-molecule gene-switch studies contain enough matched functional, pharmacokinetic, and orthogonality information to support a clinically interpretable exposure-activation assessment?

It includes:

clear rationale and research question
objectives
inclusion and exclusion criteria
database-search and screening plan
extraction fields
a pre-specified comparability framework
a 7-point Translation Readiness Evidence Score
primary and secondary outcomes
ethics statement, timeline, feasibility, limitations, and references

This positioning fits the ICMR STS objective of helping undergraduates learn research methods, while keeping the project achievable without laboratory work or human participants. The ICMR STS page describes the program as an opportunity for undergraduate medical students to gain research-methodology experience.

Download the Word proposal here:

ICMR STS Proposal Gene Switch Translation Readiness

Word Document · DOCX

Before submission, replace the bracketed student and guide details, have your guide confirm the scope, and obtain a written IEC exemption or determination according to Osmania Medical College policy.

But I don’t want to change the research totally

Reading File

You do not need to change the core research idea.

Your original idea is:

Compare the concentration that activates engineered switches with concentrations humans may be exposed to, including therapeutic drugs, metabolites, endogenous molecules, and common environmental chemicals.

That remains the heart of the study.

What needs changing is only the claim and method wording, so a reviewer cannot reject it for overclaiming.

Keep these parts exactly

Tet-On and doxycycline
Trimethoprim degron
Sirolimus / FKBP-FRB
CreERT2 / 4-OHT and endoxifen
AID, AID2, natural IAA and synthetic auxins
Environmental, dietary, endogenous, and prescribed-drug exposure
The concern about accidental or background activation
The idea of comparing activation concentration with real human exposure
The cumulative probability concept, if clearly marked as an illustrative sensitivity analysis

Change only these parts

Original wording	Better wording
“This proves accidental activation in humans”	“This identifies plausible exposure-overlap signals requiring construct-specific testing.”
“MoE is a regulatory safety margin”	“Activation-to-exposure ratio is an exploratory screening measure.”
“All values can be compared”	“Only matched ligand, compartment, endpoint, and exposure-duration values will be quantitatively compared.”
“Human exposure activates the switch”	“Published systemic exposure overlaps with a published in-vitro functional concentration range.”
“Safe / unsafe switch”	“Lower-priority or higher-priority system for preclinical follow-up.”

That is not changing your research. It is protecting it from being scientifically attacked.

Your project, preserved and strengthened

Recommended title

Exposure-Overlap Screening of Chemical Gene Switches: A Scoping Review of Human Drug, Endogenous Metabolite and Environmental Trigger Concentrations

This still sounds like your actual project.

A slightly more formal alternative:

Potential Exposure Overlap Between Human Chemical Exposures and Activation Thresholds of Mammalian Gene Switches: A Scoping Review

Your original research question, rewritten accurately

Among mammalian chemical gene switches with therapeutic or translational applications, do reported human exposures to their triggers, related metabolites, endogenous molecules, or environmental analogues overlap with reported functional activation concentrations?

That is the same idea you started with.

Main aim

To identify possible overlap between published human chemical-exposure concentrations and published functional activation concentrations of mammalian gene-switch systems, and to classify the strength and limitations of each comparison.

Primary objective

To calculate an exploratory activation-to-exposure ratio where the exact ligand, functional endpoint, units, and compartment are sufficiently matched.

[ \text{Exploratory activation-to-exposure ratio}

\frac{\text{functional activation concentration}}{\text{maximum relevant human exposure concentration}} ]

Interpret it carefully:

Ratio <1: reported human exposure is at or above the reported functional concentration. This is a signal for follow-up, not proof of human activation.
Ratio 1 to 10: limited numerical separation.
Ratio >10: greater numerical separation, but still not proof of absence of activation.
Not calculable: wrong ligand, missing human PK, only a Kd, incompatible compartment, or missing functional threshold.

That preserves your SEM/MoE concept but fixes its weak point: it becomes a screening ratio, not a regulatory conclusion.

The one crucial rule for your table

Do not remove rows. Instead, add a column called:

Validity of quantitative comparison

Use three labels:

Label	Meaning
Directly comparable	Same chemical, functional endpoint, usable human PK, compatible units and compartment
Exploratory comparison	Same chemical but one important limitation, such as plasma used as a proxy for tissue
Not calculable	Different ligand, metabolite, analogue, missing PK, only a working concentration, or incompatible data

This is exactly how you retain your interesting findings without pretending they are stronger than they are.

Your final table could look like this

System	Trigger / exposure source	Functional reference point	Human exposure metric	Ratio	Validity	Meaning
Tet-On	Doxycycline, standard-dose Cmax	Lowest reported functional concentration	Plasma Cmax	<1	Exploratory	Prioritise for duration-matched testing
ecDHFR-DD	TMP, standard and high-dose therapy	Full-stabilisation concentration	Plasma Cmax	Variable	Exploratory	Working concentration, not onset threshold
FKBP-FRB	Sirolimus therapeutic exposure	Functional activation concentration	Converted plasma trough	To verify	Exploratory	Whole-blood to plasma conversion required
CreERT2	4-OHT in tamoxifen treatment	4-OHT functional EC50	Plasma concentration	<1	Exploratory	Construct-specific tissue testing needed
CreERT2	Endoxifen	No matched endoxifen threshold	Plasma concentration	Not calculable	Not calculable	Must not use 4-OHT EC50
Wild-type AID	Endogenous IAA	Functional degradation reference point	Circulating IAA	Exploratory	Exploratory	Does not prove activation in humans
AID2	Natural IAA	Threshold is for 5-Ph-IAA	Natural IAA	Not calculable	Not calculable	Different ligand
Super-sensitive AID	Natural IAA	Threshold is for 5-Ad-IAA	Natural IAA	Not calculable	Not calculable	Different ligand
AID / agricultural auxin	NAA or 2,4-D	Functional activation data	Dietary residue only	Not calculable	Not calculable	Food residue is not plasma PK

This is still your research. In fact, it is stronger, because the “not calculable” findings are themselves important.

What is genuinely novel in your version

Your distinctive contribution is not merely making a table of gene switches.

It is asking this question across systems:

“Could chemicals already present in patients, through medicines, endogenous metabolites, diet, consumer products, or environmental exposure, overlap with the concentration range that controls an engineered switch?”

Then you show why the field often cannot answer this from published data because studies do not report:

the correct functional threshold
duration of activation
matched human PK
free or tissue concentration
exact ligand specificity
endogenous-ligand cross-reactivity

That is a meaningful result.

Your revised conclusion should be

“This review does not establish unintended activation in humans. It identifies published exposure-overlap signals and separates them from invalid or non-comparable comparisons. The findings provide a structured basis for selecting trigger-switch pairs and prioritising construct-specific pharmacokinetic-pharmacodynamic testing before clinical translation.”

So no, do not abandon the research. Keep the original biological question. Just make the project:

Compare when comparison is valid
Refuse to calculate when it is invalid
Report uncertainty honestly
Present overlap as a preclinical warning signal, not proof of harm

That makes it more likely, not less likely, to survive ICMR review.

So draft this in your document before like Same for icmr but a little true to the idea

Reading File

Browsing Directory

/tmp/workspace

Searching the Web

site:icmr.gov.in short term studentship STS undergraduate medical research methodology 2026

Running Command

python3 - <<'PY' from docx import Document p='/tmp/workspace/icmr-sts-gene-switch-proposal/output/ICMR_STS_Proposal_Gene_Switch_Translation_Readiness.docx' d=Document(p) for i,x in enumerate(d.paragraphs[:35]): if x.text.strip(): print(f'{i}: {x.text}') PY

Running Command

python3 - <<'PY' from docx import Document from docx.shared import Pt from pathlib import Path src=Path('/tmp/workspace/icmr-sts-gene-switch-proposal/output/ICMR_STS_Proposal_Gene_Switch_Translation_Readiness.docx') out=Path('/tmp/workspace/icmr-sts-gene-switch-proposal/output/ICMR_STS_Proposal_Exposure_Overlap_Gene_Switches.docx') d=Document(src) # Replace exact main text while retaining professional layout. repl={ 'Clinical Translation Readiness of Small-Molecule-Controlled Mammalian Gene Switches: A Scoping Review of Functional Activation, Human Pharmacokinetics and Orthogonality Evidence':'Potential Exposure Overlap Between Human Chemical Exposures and Functional Activation Concentrations of Mammalian Gene Switches: A Scoping Review', 'Protocol for a literature-based evidence-mapping study':'Protocol for an exploratory exposure-overlap screening and evidence-mapping study', 'Small-molecule-responsive gene switches are engineered systems that permit external control of gene expression, protein degradation, cell survival, or immune-cell activity. They are being developed for cell and gene therapy, including CAR-T-cell and implantable-cell applications. Their clinical utility depends not only on whether a switch works in cultured cells, but also on whether its trigger has an acceptable human safety profile, pharmacokinetic profile, and degree of biological orthogonality.':'Small-molecule-responsive gene switches are engineered systems that permit external control of gene expression, protein degradation, cell survival, or immune-cell activity. They are used in experimental biology and are being developed for cell and gene therapy, including CAR-T-cell and implantable-cell applications. A key translational question is whether concentrations of a switch trigger, a related active metabolite, an endogenous molecule, or an environmental analogue that humans may encounter could overlap with concentrations reported to produce functional switch activity in laboratory systems.', 'Existing reviews describe small-molecule regulators and translational challenges of gene switches. However, reported activation data are heterogeneous: studies may report a binding affinity, a single working concentration, or a functional concentration-response curve. Human exposure data may be reported as plasma Cmax, whole-blood trough concentration, average steady-state concentration, or no human pharmacokinetic value. These values are often not directly comparable. A transparent evidence map is needed to identify whether a published switch has enough matched information for a clinically interpretable exposure-activation assessment.':'Existing reviews describe small-molecule regulators and translational challenges of gene switches. However, published studies do not consistently place functional activation data beside relevant human exposure data. Activation may be reported as a binding affinity, a single working concentration, or a functional concentration-response curve. Human exposure may be reported as plasma Cmax, whole-blood trough concentration, steady-state concentration, dietary residue, endogenous-metabolite concentration, or may be unavailable. A structured exposure-overlap screen is needed to distinguish possible overlap signals from comparisons that are invalid or too incomplete for quantitative interpretation.', 'This study will not estimate clinical risk, claim accidental activation in humans, or recommend clinical use of a specific switch. Its purpose is to map the completeness and comparability of the published evidence needed before such questions can be tested experimentally.':'This study will not estimate clinical risk, claim accidental activation in humans, or recommend clinical use of a specific switch. It will identify possible published exposure-overlap signals and, equally importantly, identify comparisons that cannot be calculated because the ligand, endpoint, exposure duration, compartment, or human-exposure data do not match. Such findings can guide construct-specific preclinical pharmacokinetic-pharmacodynamic testing.', 'Among small-molecule-controlled mammalian gene switches proposed for therapeutic, implantable-cell, gene-therapy, or engineered immune-cell applications, how often does the published literature provide sufficient matched functional, pharmacokinetic, and orthogonality evidence for a clinically interpretable activation-exposure assessment?':'Among mammalian chemical gene switches with therapeutic or translational applications, do published human exposures to the trigger, related active metabolites, endogenous molecules, or environmental analogues overlap with reported functional activation concentrations, and how valid is each quantitative comparison?', 'To map the clinical translation readiness of small-molecule-controlled mammalian gene switches by assessing the completeness and comparability of published functional activation, human pharmacokinetic, and orthogonality evidence.':'To identify and classify possible overlap between published human chemical-exposure concentrations and published functional activation concentrations of mammalian gene-switch systems, while explicitly documenting the validity and limitations of each comparison.', 'To identify published small-molecule-controlled mammalian gene switches with a stated therapeutic, implantable-cell, gene-therapy, or engineered immune-cell application.':'To identify mammalian chemical gene switches with a stated therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or other translational application.', 'To extract the exact trigger, switch construct, functional endpoint, concentration-response evidence, and exposure duration reported for each eligible system.':'To extract the exact trigger, switch construct, functional endpoint, activation concentration or concentration-response evidence, and exposure duration reported for each eligible system.', 'To extract human pharmacokinetic evidence for the exact trigger, including concentration metric, compartment, dosing context, and source.':'To extract reported human exposure data for the exact trigger and, where relevant, its active metabolite, endogenous counterpart, or environmental analogue, including concentration metric, compartment, exposure context, and source.', 'To assess whether functional and human exposure values are directly comparable, approximately comparable, or not quantitatively comparable.':'To calculate an exploratory activation-to-exposure ratio only where values are sufficiently matched, and to classify all other comparisons as exploratory only or not calculable.', 'To classify each system using a pre-specified Translation Readiness Evidence Score and identify common evidence gaps.':'To identify exposure-overlap signals requiring construct-specific preclinical follow-up and the common evidence gaps that prevent interpretation.' } for par in d.paragraphs: if par.text in repl: # preserve first run styling as much as possible old=par.text; text=repl[old] for run in par.runs: run.text='' if par.runs: par.runs[0].text=text else: par.add_run(text) # Find key paragraphs for alteration by start for par in d.paragraphs: if par.text.startswith('5.1 Study design and reporting'): pass elif par.text.startswith('Scoping review. The protocol will be finalized'): for r in par.runs:r.text='' par.runs[0].text='Scoping review with exploratory exposure-overlap screening. The protocol will be finalized and dated before screening and data extraction. Reporting will follow PRISMA-ScR where applicable. The study will use published literature and publicly available regulatory, pharmacokinetic, dietary-exposure, and endogenous-metabolite sources. It will not involve human testing or laboratory experimentation.' elif par.text.startswith('5.5 Data extraction'): pass elif par.text.startswith('A pilot-tested extraction sheet'): for r in par.runs:r.text='' par.runs[0].text='A pilot-tested extraction sheet will be used. The guide will verify all extracted values used in final ratio calculations and a random 20% of remaining fields. Exact page, figure, table, or supplementary-figure locations will be recorded for each numerical functional value and for each human exposure value.' elif par.text.startswith('No numerical activation-to-exposure ratio will be calculated'): for r in par.runs:r.text='' par.runs[0].text='For directly comparable or exploratory comparisons, the activation-to-exposure ratio will be calculated as: functional activation concentration divided by the maximum relevant reported human exposure concentration. A ratio below 1 will be reported as a possible numerical overlap signal, 1 to 10 as limited numerical separation, and above 10 as greater numerical separation. These categories do not establish clinical activation, safety, or absence of activation. No ratio will be calculated where the comparison is not quantitatively comparable. This metric is an exploratory screening ratio, not a regulatory Margin of Exposure.' elif par.text.startswith('Each switch-trigger pair will receive one point'): for r in par.runs:r.text='' par.runs[0].text='Each switch-exposure comparison will receive one point for each item below, maximum 7. This is an evidence-completeness tool accompanying the exposure-overlap screen, not a validated clinical safety score.' elif par.text.startswith('Primary outcome: proportion of eligible'): for r in par.runs:r.text='' par.runs[0].text='Primary outcome: proportion of eligible switch-exposure comparisons with an exploratory activation-to-exposure ratio below 1, 1 to 10, above 10, or not calculable, together with the validity category for each comparison.' elif par.text.startswith('Secondary outcomes: median Translation'): for r in par.runs:r.text='' par.runs[0].text='Secondary outcomes: median evidence-completeness score with interquartile range; proportion reporting concentration-response data, exposure duration, exact-trigger human PK, compartment information, and endogenous/off-target assessment; frequency of exposure sources (therapeutic drug, active metabolite, endogenous molecule, environmental/dietary analogue); and frequency of each missing-data domain.' elif par.text.startswith('Data will be summarized with counts'): for r in par.runs:r.text='' par.runs[0].text='Data will be summarized with counts and percentages. No meta-analysis will be performed because switch architectures, triggers, exposure sources, endpoints, assay conditions, and PK metrics are expected to be heterogeneous. Results will be presented as an exposure-overlap matrix, a validity-of-comparison column, bar charts of missing-data domains, and a narrative synthesis.' elif par.text.startswith('The study will produce:'): for r in par.runs:r.text='' par.runs[0].text='The study will produce: (i) a structured exposure-overlap matrix for mammalian chemical gene switches; (ii) a classification of each comparison as directly comparable, exploratory only, or not calculable; (iii) a checklist of minimum information required before an activation-to-exposure comparison can be interpreted; and (iv) a prioritized list of switch-exposure pairs that warrant construct-specific preclinical testing.' elif par.text.startswith('The study will not identify safe or unsafe products'): for r in par.runs:r.text='' par.runs[0].text='The study will not label products or switches as safe or unsafe. It will identify possible numerical exposure-overlap signals in published data, separate these from invalid comparisons, and identify where additional construct-specific preclinical studies are needed.' elif par.text.startswith('The project requires access'): for r in par.runs:r.text='' par.runs[0].text='The project requires access to bibliographic databases, reference-management software, spreadsheet software, and guide supervision. It does not require laboratory equipment, patient recruitment, drug administration, or funding for assays. Anticipated limitations include publication bias, incomplete reporting, heterogeneity of constructs and assays, and inability to infer tissue-level exposure or clinical activation from published systemic concentrations. These limits will be stated explicitly for each calculated ratio.' # Update tables by text substitutions for t in d.tables: for row in t.rows: for c in row.cells: val=c.text cellrepl={ 'Human PK':'Human exposure', 'Exact trigger; dose/regimen; Cmax, trough, average concentration, AUC where reported; total/free concentration; compartment; source.':'Exact trigger, active metabolite, endogenous counterpart, or environmental analogue; exposure route/context; Cmax, trough, average concentration, AUC, dietary residue, or endogenous concentration where reported; total/free concentration; compartment; source.', 'Comparability':'Ratio validity', 'Ligand match; unit conversion; compartment match; time/exposure match; explicit limitations.':'Exact ligand/chemical match; unit conversion; compartment match; time/exposure match; source of exposure; explicit limitations.', 'Orthogonality / safety':'Orthogonality / biological relevance', 'Known endogenous activity, established pharmacological target, clinically relevant adverse effects, and reported endogenous/environmental cross-reactivity.':'Known endogenous activity, established pharmacological target, clinically relevant adverse effects, and reported endogenous/environmental cross-reactivity.', 'Directly comparable':'Directly comparable', 'Exact trigger is used in both sources; functional endpoint is reported in mammalian cells; exposure duration is reported; human PK is available; and compartment is the same or a published conversion is available.':'Exact chemical is compared; functional endpoint is reported in mammalian cells; exposure duration is reported; relevant human exposure is available; and compartment is the same or a published conversion is available.', 'Approximate comparison only':'Exploratory comparison', 'Exact trigger and functional evidence are available, but one or more major limitations remain, such as total rather than free concentration, plasma used as a proxy for target tissue, or unmatched exposure duration.':'Exact chemical and functional evidence are available, but one or more major limitations remain, such as total rather than free concentration, plasma used as a proxy for target tissue, or unmatched exposure duration.', 'Not quantitatively comparable':'Not calculable', 'Different ligand/metabolite/analogue is used; only binding Kd or a working dose is available; no human PK exists for the trigger; or compartments/units cannot be reconciled.':'Different chemical, metabolite, or analogue is used; only binding Kd or a working dose is available; no relevant human exposure value exists; or compartments/units cannot be reconciled.', } if val in cellrepl: c.paragraphs[0].clear(); c.paragraphs[0].add_run(cellrepl[val]) # Heading score rename and general uses for par in d.paragraphs: if par.text=='5.7 Translation Readiness Evidence Score': for r in par.runs:r.text='' par.runs[0].text='5.7 Evidence-Completeness Score for Exposure-Overlap Assessment' if par.text.startswith('Score interpretation:'): for r in par.runs:r.text='' par.runs[0].text='Score interpretation: 0 to 2, insufficient evidence for quantitative exposure-overlap assessment; 3 to 5, exploratory assessment with material gaps; 6 to 7, comparatively well characterized for preclinical exposure-overlap assessment. The score is descriptive and will not be used to rank patient safety.' # Add an explicit section just before Ethics by creating at end is easier but it is substantive, add before refs? paragraph append # Save # Add note after methods using paragraphs insertion omitted due API complexity; covered. d.save(out) print(out) PY python3 - <<'PY' from docx import Document p='/tmp/workspace/icmr-sts-gene-switch-proposal/output/ICMR_STS_Proposal_Exposure_Overlap_Gene_Switches.docx' d=Document(p) for i in [1,4,5,6,8,10,12,15,30,34,40]: print(i, d.paragraphs[i].text) print('tables',len(d.tables),'paras',len(d.paragraphs)) PY

Running Command

python3 - <<'PY' from docx import Document p='/tmp/workspace/icmr-sts-gene-switch-proposal/output/ICMR_STS_Proposal_Exposure_Overlap_Gene_Switches.docx' d=Document(p) checks=['Potential Exposure Overlap','activation-to-exposure ratio','not calculable','clinical risk'] text='\n'.join(x.text for x in d.paragraphs)+'\n'+'\n'.join(c.text for t in d.tables for r in t.rows for c in r.cells) for x in checks: print(x, text.lower().count(x.lower())) print('last modified title:',d.paragraphs[1].text) for ti in [2,3,4]: print('TABLE',ti) for r in d.tables[ti].rows[:3]: print(' | '.join(c.text[:150] for c in r.cells)) PY

I revised the proposal without changing your core idea.

The revised version now keeps:

comparison of switch activation concentrations with human exposures
therapeutic drugs, active metabolites, endogenous molecules, dietary or environmental analogues
exploratory activation-to-exposure ratio
identification of possible exposure-overlap signals
Tet-On, sirolimus, tamoxifen/CreERT2, AID systems, and related trigger families as eligible examples

It changes only the scientific framing:

a ratio below 1 is a possible overlap signal, not proof of human activation
comparisons with different ligands, missing human exposure data, Kd-only data, or incompatible compartments are not calculable
it includes a validity category for every comparison
it remains an ICMR-feasible literature-based scoping review

Download the revised proposal:

ICMR STS Proposal Exposure Overlap Gene Switches

Word Document · DOCX

Hey is this for icmr initial submission or a report

It is a detailed initial proposal draft, not the final ICMR STS report.

You would use it to:

Discuss the project with your guide.
Get the title, methods, and scope approved.
Condense or copy its sections into the exact ICMR STS online proposal form when the next call opens.
Obtain IEC exemption or the institutional determination required by your college.

It is too detailed for most initial online submission forms. The ICMR STS portal normally asks for a shorter structured proposal, often with title, background, objectives, methodology, ethics, expected outcome, timeline, and references.

The final report comes only after you complete the study. It would contain:

actual search dates and databases searched
PRISMA flow diagram
number of articles found and included
completed evidence tables
calculated exploratory ratios where valid
results and discussion
final conclusions
completed reference list and appendices

So think of the Word file as your master protocol/proposal. It is the source document from which you make the initial ICMR submission, not the report you submit at the end.

So make a icmr report for accepting in 2027 submissions

Reading File

Browsing Directory

~/icmr-sts-gene-switch-proposal

Running Command

mkdir -p "/tmp/workspace/icmr-sts-2027-initial-submission/output" "/tmp/workspace/icmr-sts-2027-initial-submission/src" && python3 - <<'PY' from docx import Document from docx.shared import Inches, Pt from docx.enum.text import WD_ALIGN_PARAGRAPH from docx.enum.table import WD_TABLE_ALIGNMENT, WD_CELL_VERTICAL_ALIGNMENT from docx.oxml import OxmlElement from docx.oxml.ns import qn from pathlib import Path out=Path('/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches.docx') d=Document(); s=d.sections[0] s.top_margin=Inches(.65);s.bottom_margin=Inches(.65);s.left_margin=Inches(.75);s.right_margin=Inches(.75) for name in ['Normal','Title','Heading 1','Heading 2']: st=d.styles[name]; st.font.name='Arial'; st._element.rPr.rFonts.set(qn('w:eastAsia'),'Arial') d.styles['Normal'].font.size=Pt(10);d.styles['Normal'].paragraph_format.space_after=Pt(4) d.styles['Title'].font.size=Pt(15); d.styles['Heading 1'].font.size=Pt(11.5);d.styles['Heading 2'].font.size=Pt(10.5) def shade(cell, color): p=cell._tc.get_or_add_tcPr(); x=OxmlElement('w:shd');x.set(qn('w:fill'),color);p.append(x) def tbl(rows, widths): t=d.add_table(rows=0,cols=len(rows[0]));t.style='Table Grid';t.alignment=WD_TABLE_ALIGNMENT.CENTER for i,row in enumerate(rows): cs=t.add_row().cells for j,v in enumerate(row): cs[j].text='';p=cs[j].paragraphs[0];r=p.add_run(v);r.font.name='Arial';r.font.size=Pt(9);r.bold=(i==0) cs[j].vertical_alignment=WD_CELL_VERTICAL_ALIGNMENT.CENTER if i==0:shade(cs[j],'D9EAF7') cs[j].width=Inches(widths[j]) return t def para(x='',bold=False,align=None): p=d.add_paragraph(); if align:p.alignment=align r=p.add_run(x);r.bold=bold return p def head(x):d.add_heading(x,level=1) def bullets(xs): for x in xs: p=d.add_paragraph(style='List Bullet');p.add_run(x) para('ICMR SHORT-TERM STUDENTSHIP (STS) 2027',True,WD_ALIGN_PARAGRAPH.CENTER) p=para('INITIAL RESEARCH PROPOSAL',True,WD_ALIGN_PARAGRAPH.CENTER);p.runs[0].font.size=Pt(13) p=para('Potential Exposure Overlap Between Human Chemical Exposures and Functional Activation Concentrations of Mammalian Gene Switches: A Scoping Review',True,WD_ALIGN_PARAGRAPH.CENTER);p.runs[0].font.size=Pt(15) para('For adaptation to the official 2027 ICMR STS online form once the call and word limits are released.',False,WD_ALIGN_PARAGRAPH.CENTER) tbl([ ['Field','Details'], ['Student investigator','[Name], Second-year MBBS, Osmania Medical College'], ['Guide','[Name, Department, designation]'], ['Institution','Osmania Medical College, Hyderabad, Telangana'], ['Proposed duration','8 weeks after selection and institutional approval'], ['Study design','Literature-based scoping review and exploratory exposure-overlap screening'], ['Human participants / specimens','None'] ],[1.85,5.0]) head('1. Title') para('Potential Exposure Overlap Between Human Chemical Exposures and Functional Activation Concentrations of Mammalian Gene Switches: A Scoping Review') head('2. Background and rationale') para('Small-molecule-controlled gene switches allow external control of gene expression, protein degradation, apoptosis, or immune-cell activity. Such systems are used in experimental biology and are being developed for cell therapy, gene therapy, engineered immune cells, and implantable designer-cell systems. A practical translational question is whether concentrations of a switch trigger, a related active metabolite, an endogenous molecule, or an environmental analogue that humans may encounter could numerically overlap with concentrations reported to produce functional switch activity in laboratory systems.') para('This question cannot be answered by simply dividing two numbers. Published functional evidence may be a binding constant, a working concentration, or a concentration-response curve; human exposure may be reported as plasma Cmax, trough, steady-state concentration, endogenous metabolite level, or dietary residue. The source chemical, assay endpoint, duration, units, and compartment may not match. A structured review is therefore needed to identify possible exposure-overlap signals while separating them from comparisons that are invalid or not calculable.') para('The project is relevant to the safe design of emerging engineered-cell therapies. It does not claim that any switch is unsafe or that unintended activation occurs in humans. It identifies published signals that require construct-specific preclinical pharmacokinetic-pharmacodynamic testing.') head('3. Research question') para('Among mammalian chemical gene switches with therapeutic or translational applications, do published human exposures to the trigger, related active metabolites, endogenous molecules, or environmental analogues overlap with reported functional activation concentrations, and how valid is each quantitative comparison?') head('4. Aim') para('To identify and classify possible overlap between published human chemical-exposure concentrations and published functional activation concentrations of mammalian gene-switch systems, while explicitly documenting the validity and limitations of each comparison.') head('5. Objectives') bullets([ 'To identify published mammalian chemical gene switches with therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or other translational applications.', 'To extract the exact trigger, switch construct, functional endpoint, activation concentration or concentration-response evidence, and exposure duration.', 'To extract human exposure data for the exact trigger and, where relevant, active metabolites, endogenous counterparts, or environmental analogues.', 'To calculate an exploratory activation-to-exposure ratio only when ligand identity, endpoint, units, and compartment are sufficiently matched.', 'To classify comparisons as directly comparable, exploratory only, or not calculable, and identify evidence gaps requiring preclinical follow-up.' ]) head('6. Methodology') para('Study design: Scoping review with exploratory exposure-overlap screening. The protocol and extraction form will be dated before screening. Reporting will follow PRISMA-ScR principles where applicable.') para('Information sources: PubMed, Google Scholar, and Scopus or Web of Science if institutional access is available, from inception to the final search date. Reference lists of eligible studies and key reviews will be screened. Human exposure information will be obtained preferentially from regulatory drug labels and original human pharmacokinetic studies. Data on endogenous compounds or environmental exposures will be extracted from primary human biomonitoring, exposure, or pharmacokinetic studies.') para('Provisional search terms: ("gene switch" OR "inducible gene" OR "chemical inducible" OR "small molecule inducible" OR "chemically induced dimerization" OR "drug-controlled") AND (mammalian OR "cell therapy" OR "gene therapy" OR "T cell" OR therapeutic). Search strings, date, and record counts will be retained.') para('Eligibility: Original English-language studies reporting a small-molecule-controlled system in mammalian cells and a therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or stated translational application will be included. Purely microbial or plant systems, reviews used only for citation chasing, and studies without sufficient information to identify a trigger-switch pair will be excluded.') para('Screening: Records will be deduplicated in Zotero. The student will screen titles/abstracts and full texts. The guide will independently verify uncertain full-text decisions and a random 20% of title/abstract decisions. A selection flow diagram will be created.') para('Data extraction: For each unique switch-trigger pair, the following will be recorded: switch components and intended application; exact chemical trigger; whether the exposure is the trigger itself, a metabolite, endogenous molecule, or environmental analogue; functional endpoint; lowest observed effect and/or ECx where reported; working concentration; exposure duration; human exposure metric; dose or exposure context; compartment; total versus free concentration; and exact source figure/table/page.') head('7. Exposure-overlap assessment') para('Exploratory activation-to-exposure ratio:') p=para('Functional activation concentration ÷ maximum relevant reported human exposure concentration',True,WD_ALIGN_PARAGRAPH.CENTER) para('The ratio will be calculated only for directly comparable or exploratory comparisons. A ratio below 1 will be described as a possible numerical exposure-overlap signal; 1 to 10 as limited numerical separation; and above 10 as greater numerical separation. These categories do not prove activation in humans, clinical risk, safety, or absence of activation. The measure is not a regulatory Margin of Exposure.') tbl([ ['Category','Rule'], ['Directly comparable','Exact chemical is used in both sources; a functional mammalian-cell endpoint and exposure duration are reported; relevant human exposure data are available; and compartments are matched or a published conversion is available.'], ['Exploratory only','Exact chemical and functional evidence are available, but a major limitation remains, for example plasma used as a proxy for target tissue, total rather than free concentration, or unmatched duration.'], ['Not calculable','Different chemical, metabolite, or analogue is used; only a binding Kd or working concentration is available; no relevant human exposure value exists; or units/compartments cannot be reconciled.'] ],[1.55,5.3]) head('8. Outcomes and analysis') para('Primary outcome: The proportion of eligible switch-exposure comparisons with exploratory ratios below 1, 1 to 10, above 10, or not calculable, presented together with their validity category.') para('Secondary outcomes: The proportions of studies reporting functional concentration-response data, exposure duration, exact-trigger human pharmacokinetics, compartment information, and assessment of endogenous/off-target cross-reactivity; the source of exposure, such as prescribed drug, metabolite, endogenous molecule, or environmental/dietary analogue; and the most frequent reasons a comparison cannot be calculated.') para('Analysis: Data will be summarized as counts and percentages. No meta-analysis will be undertaken because switch designs, chemicals, endpoints, exposure sources, and assay conditions are heterogeneous. Results will be shown in an evidence matrix, a flow diagram, and descriptive figures of evidence gaps.') head('9. Ethics') para('The study uses published literature and publicly available regulatory/exposure sources only. There will be no participant recruitment, clinical intervention, access to medical records, biological samples, or identifiable personal data. Institutional Ethics Committee exemption or a written determination of exemption will be sought according to Osmania Medical College policy before the study begins.') head('10. Expected outcome and significance') para('The study will produce an evidence matrix that identifies: (a) possible numerical exposure-overlap signals; (b) comparisons that are too incomplete or mismatched to calculate; and (c) the specific data needed for proper preclinical follow-up. It may help researchers select chemical triggers more carefully and report the pharmacokinetic, functional, and ligand-specificity information required for translation of engineered-cell systems.') head('11. Work plan') tbl([ ['Week','Activity'], ['1','Protocol finalization, guide review, IEC exemption/determination, pilot search and extraction form.'], ['2','Database search, deduplication, title/abstract screening.'], ['3-4','Full-text screening, citation chasing, and identification of human exposure sources.'], ['5-6','Data extraction, guide verification, ratio calculation where valid, evidence classification.'], ['7','Analysis, flow diagram, evidence matrix, figures, and first report draft.'], ['8','Guide review, revisions, final STS report preparation.'] ],[.65,6.2]) head('12. Feasibility and limitations') para('The study is feasible within the STS period because it requires only literature databases, reference-management software, spreadsheet software, and guide supervision. It requires no laboratory work, patient recruitment, or drug administration. Limitations include incomplete reporting, publication bias, variation between assays and constructs, and inability to infer target-tissue exposure or clinical activation from systemic published concentrations. These limitations will be displayed rather than concealed.') head('13. Selected references') for x in [ 'Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467-473. doi:10.7326/M18-0850.', 'Siddiqui MM, Tous C, Wong WW. Small molecule-inducible gene regulatory systems in mammalian cells: progress and design principles. Curr Opin Biotechnol. 2022;78:102823. doi:10.1016/j.copbio.2022.102823.', 'Mansouri M, Fussenegger M. Small-Molecule Regulators for Gene Switches to Program Mammalian Cell Behaviour. ChemBioChem. 2024;25:e202300717. doi:10.1002/cbic.202300717.', 'Galvan S, Teixeira AP, Fussenegger M. Enhancing cell-based therapies with synthetic gene circuits responsive to molecular stimuli. Biotechnol Bioeng. 2024;121:2987-3000. doi:10.1002/bit.28770.', 'Chin SE, Schindler C, Vinall L, et al. A simeprevir-inducible molecular switch for the control of cell and gene therapies. Nat Commun. 2023;14:7840. doi:10.1038/s41467-023-43484-9.', 'ICMR. Short-Term Studentship (STS). Available from: https://www.icmr.gov.in/short-term-studentship-sts. Accessed 21 September 2026.' ]: p=d.add_paragraph(style='List Number');p.add_run(x) foot=s.footer.paragraphs[0];foot.alignment=WD_ALIGN_PARAGRAPH.CENTER;foot.add_run('Draft for anticipated ICMR STS 2027 initial submission. Update to the official 2027 form and call instructions before submitting.').font.size=Pt(8) d.save(out) print(out) PY python3 - <<'PY' from docx import Document p='/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches.docx' d=Document(p) text='\n'.join(x.text for x in d.paragraphs) print('paragraphs',len(d.paragraphs),'tables',len(d.tables),'words',len(text.split())) print(d.paragraphs[2].text) print(d.paragraphs[7].text) PY

I made the concise initial ICMR STS submission proposal, not a final report.

It is about 1,200 words and retains your original idea:

compares functional activation concentrations of gene switches with human exposures
includes drugs, metabolites, endogenous compounds, and environmental analogues
calculates an exploratory ratio only when comparison is valid
labels mismatched comparisons as “not calculable”
does not overclaim that activation occurs in humans

It is designed to be adapted into the official ICMR STS 2027 online application form once ICMR releases its exact fields, limits, and instructions.

ICMR STS 2027 Initial Proposal Exposure Overlap Gene Switches

Word Document · DOCX

Replace the bracketed student and guide details, then have your guide review the title, scope, and ethics-exemption wording before submission.

Now this will be flagged as ai based so humanise it a little

Reading File

Browsing Directory

~/icmr-sts-2027-initial-submission

I can make it clearer, less formulaic, and closer to how a well-prepared second-year student would write. I cannot help to defeat AI detection or guarantee how a detector will score it. I will keep the scientific meaning, remove overly polished phrasing, and make the wording more direct.

Running Command

python3 - <<'PY' from docx import Document p='/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches.docx' d=Document(p) for i,x in enumerate(d.paragraphs): if x.text.strip(): print(i, x.text) PY

Running Command

python3 - <<'PY' from docx import Document from pathlib import Path src=Path('/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches.docx') out=Path('/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches_Natural_Draft.docx') d=Document(src) replacements={ 'Small-molecule-controlled gene switches allow external control of gene expression, protein degradation, apoptosis, or immune-cell activity. Such systems are used in experimental biology and are being developed for cell therapy, gene therapy, engineered immune cells, and implantable designer-cell systems. A practical translational question is whether concentrations of a switch trigger, a related active metabolite, an endogenous molecule, or an environmental analogue that humans may encounter could numerically overlap with concentrations reported to produce functional switch activity in laboratory systems.':'Small-molecule-controlled gene switches are systems designed to turn a cellular function on or off after exposure to a chosen chemical. Depending on the system, the response may be gene expression, protein degradation, apoptosis, or a change in immune-cell activity. These switches are widely used in experimental biology and are also being explored for cell therapy, gene therapy, and engineered immune-cell applications. Before such systems are considered for clinical use, it is reasonable to ask whether chemicals already encountered by patients, such as prescribed drugs, metabolites, or naturally occurring molecules, could reach concentrations similar to those used to activate the switch in laboratory studies.', 'This question cannot be answered by simply dividing two numbers. Published functional evidence may be a binding constant, a working concentration, or a concentration-response curve; human exposure may be reported as plasma Cmax, trough, steady-state concentration, endogenous metabolite level, or dietary residue. The source chemical, assay endpoint, duration, units, and compartment may not match. A structured review is therefore needed to identify possible exposure-overlap signals while separating them from comparisons that are invalid or not calculable.':'This is not as simple as dividing one number by another. A switch paper may report a binding constant, a single laboratory working dose, or a proper concentration-response curve. Human exposure can be reported as a peak concentration (Cmax), a trough concentration just before the next dose, a steady-state value, or an endogenous-metabolite level. In many cases the chemical, endpoint, duration of exposure, units, or biological compartment do not match. This review will look for possible exposure-overlap signals, but will also clearly mark comparisons that are too weak or mismatched to calculate.', 'The project is relevant to the safe design of emerging engineered-cell therapies. It does not claim that any switch is unsafe or that unintended activation occurs in humans. It identifies published signals that require construct-specific preclinical pharmacokinetic-pharmacodynamic testing.':'The project is relevant to the early safety assessment of engineered-cell therapies. It will not claim that a switch is unsafe or that unintended activation occurs in people. Instead, it will point out which switch-exposure pairs deserve more focused preclinical testing in the relevant construct and cell type.', 'Among mammalian chemical gene switches with therapeutic or translational applications, do published human exposures to the trigger, related active metabolites, endogenous molecules, or environmental analogues overlap with reported functional activation concentrations, and how valid is each quantitative comparison?':'For mammalian chemical gene switches with therapeutic or translational applications, are published human exposure levels of the trigger, related active metabolites, endogenous molecules, or environmental analogues close to the concentrations reported to cause functional activation? Where a comparison can be made, how reliable is it?', 'To identify and classify possible overlap between published human chemical-exposure concentrations and published functional activation concentrations of mammalian gene-switch systems, while explicitly documenting the validity and limitations of each comparison.':'To examine whether published human chemical-exposure concentrations may overlap with published functional activation concentrations of mammalian gene-switch systems, and to state clearly how strong or limited each comparison is.', 'To identify published mammalian chemical gene switches with therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or other translational applications.':'To identify published mammalian chemical gene switches that have a therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or other stated translational application.', 'To extract the exact trigger, switch construct, functional endpoint, activation concentration or concentration-response evidence, and exposure duration.':'To record the exact trigger, switch construct, functional endpoint, reported activation concentration or concentration-response data, and duration of exposure.', 'To extract human exposure data for the exact trigger and, where relevant, active metabolites, endogenous counterparts, or environmental analogues.':'To collect human exposure data for the exact trigger and, where relevant, an active metabolite, endogenous counterpart, or environmental analogue.', 'To calculate an exploratory activation-to-exposure ratio only when ligand identity, endpoint, units, and compartment are sufficiently matched.':'To calculate an exploratory activation-to-exposure ratio only when the chemical, endpoint, units, and compartment are sufficiently matched.', 'To classify comparisons as directly comparable, exploratory only, or not calculable, and identify evidence gaps requiring preclinical follow-up.':'To sort comparisons into directly comparable, exploratory only, or not calculable, and identify the missing evidence that prevents a firmer conclusion.', 'Study design: Scoping review with exploratory exposure-overlap screening. The protocol and extraction form will be dated before screening. Reporting will follow PRISMA-ScR principles where applicable.':'Study design: Literature-based scoping review with an exploratory exposure-overlap screen. The protocol and data-extraction form will be finalized before screening starts. The review will be reported using PRISMA-ScR guidance where applicable.', 'Information sources: PubMed, Google Scholar, and Scopus or Web of Science if institutional access is available, from inception to the final search date. Reference lists of eligible studies and key reviews will be screened. Human exposure information will be obtained preferentially from regulatory drug labels and original human pharmacokinetic studies. Data on endogenous compounds or environmental exposures will be extracted from primary human biomonitoring, exposure, or pharmacokinetic studies.':'Information sources: PubMed and Google Scholar will be searched. Scopus or Web of Science will also be used if institutional access is available. Reference lists of included papers and relevant reviews will be checked for additional studies. For prescribed drugs, human exposure information will be taken first from regulatory labels and original pharmacokinetic studies. For endogenous compounds or environmental exposures, primary biomonitoring, exposure, or pharmacokinetic studies will be preferred.', 'Eligibility: Original English-language studies reporting a small-molecule-controlled system in mammalian cells and a therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or stated translational application will be included. Purely microbial or plant systems, reviews used only for citation chasing, and studies without sufficient information to identify a trigger-switch pair will be excluded.':'Eligibility: The review will include original English-language studies of small-molecule-controlled systems in mammalian cells where the authors describe a therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or other translational use. Microbial-only and plant-only systems will be excluded. Reviews will be used to locate primary studies but will not be used as the source of numerical data. Studies that do not identify a usable trigger-switch pair will also be excluded.', 'Screening: Records will be deduplicated in Zotero. The student will screen titles/abstracts and full texts. The guide will independently verify uncertain full-text decisions and a random 20% of title/abstract decisions. A selection flow diagram will be created.':'Screening: Records will be stored and deduplicated in Zotero. I will screen titles and abstracts first, followed by full texts. My guide will review unclear full-text decisions and a random 20% of title and abstract decisions. A study-selection flow diagram will be included.', 'Data extraction: For each unique switch-trigger pair, the following will be recorded: switch components and intended application; exact chemical trigger; whether the exposure is the trigger itself, a metabolite, endogenous molecule, or environmental analogue; functional endpoint; lowest observed effect and/or ECx where reported; working concentration; exposure duration; human exposure metric; dose or exposure context; compartment; total versus free concentration; and exact source figure/table/page.':'Data extraction: For every switch-trigger pair, I will record the switch components and intended application, the exact chemical trigger, and whether the comparison involves the trigger itself, a metabolite, an endogenous molecule, or an environmental analogue. I will also record the functional endpoint, lowest reported effect and/or ECx where available, working concentration, exposure duration, human exposure measure, dose or exposure context, biological compartment, total or free concentration, and the exact figure, table, or page where each numerical value was found.', 'The ratio will be calculated only for directly comparable or exploratory comparisons. A ratio below 1 will be described as a possible numerical exposure-overlap signal; 1 to 10 as limited numerical separation; and above 10 as greater numerical separation. These categories do not prove activation in humans, clinical risk, safety, or absence of activation. The measure is not a regulatory Margin of Exposure.':'The ratio will only be calculated when the comparison is directly comparable or can reasonably be treated as exploratory. A value below 1 will be described as a possible numerical exposure-overlap signal. A value from 1 to 10 will suggest limited numerical separation, while a value above 10 will suggest greater numerical separation. These labels do not prove activation in humans, clinical risk, safety, or absence of activation. This is an exploratory screening ratio, not a formal regulatory Margin of Exposure.', 'Primary outcome: The proportion of eligible switch-exposure comparisons with exploratory ratios below 1, 1 to 10, above 10, or not calculable, presented together with their validity category.':'Primary outcome: The proportion of eligible switch-exposure comparisons that have an exploratory ratio below 1, between 1 and 10, above 10, or cannot be calculated. Each result will be shown with its validity category.', 'Secondary outcomes: The proportions of studies reporting functional concentration-response data, exposure duration, exact-trigger human pharmacokinetics, compartment information, and assessment of endogenous/off-target cross-reactivity; the source of exposure, such as prescribed drug, metabolite, endogenous molecule, or environmental/dietary analogue; and the most frequent reasons a comparison cannot be calculated.':'Secondary outcomes: The proportion of studies that report functional concentration-response data, duration of exposure, human pharmacokinetics for the exact trigger, compartment information, and any assessment of endogenous or off-target cross-reactivity. I will also describe the source of exposure, for example a prescribed drug, metabolite, endogenous molecule, or environmental/dietary analogue, and the common reasons why comparisons could not be calculated.', 'Analysis: Data will be summarized as counts and percentages. No meta-analysis will be undertaken because switch designs, chemicals, endpoints, exposure sources, and assay conditions are heterogeneous. Results will be shown in an evidence matrix, a flow diagram, and descriptive figures of evidence gaps.':'Analysis: Findings will be summarized as counts and percentages. A meta-analysis will not be attempted because the switches, chemicals, functional endpoints, exposure sources, and assay conditions are too different to pool meaningfully. Results will be presented in an evidence matrix, a flow diagram, and simple figures showing the main evidence gaps.', 'The study uses published literature and publicly available regulatory/exposure sources only. There will be no participant recruitment, clinical intervention, access to medical records, biological samples, or identifiable personal data. Institutional Ethics Committee exemption or a written determination of exemption will be sought according to Osmania Medical College policy before the study begins.':'This study will use only published articles and publicly available regulatory or exposure sources. There will be no recruitment of participants, clinical intervention, access to hospital records, biological samples, or identifiable personal information. I will seek an Institutional Ethics Committee exemption, or written confirmation that exemption is not required, according to Osmania Medical College policy before starting the work.', 'The study will produce an evidence matrix that identifies: (a) possible numerical exposure-overlap signals; (b) comparisons that are too incomplete or mismatched to calculate; and (c) the specific data needed for proper preclinical follow-up. It may help researchers select chemical triggers more carefully and report the pharmacokinetic, functional, and ligand-specificity information required for translation of engineered-cell systems.':'The final output will be an evidence matrix showing: possible numerical exposure-overlap signals; comparisons that are too incomplete or mismatched to calculate; and the data needed before a proper preclinical follow-up study can be planned. The review may help researchers choose chemical triggers more carefully and report the pharmacokinetic, functional, and ligand-specificity details needed when moving engineered-cell systems towards clinical use.', 'The study is feasible within the STS period because it requires only literature databases, reference-management software, spreadsheet software, and guide supervision. It requires no laboratory work, patient recruitment, or drug administration. Limitations include incomplete reporting, publication bias, variation between assays and constructs, and inability to infer target-tissue exposure or clinical activation from systemic published concentrations. These limitations will be displayed rather than concealed.':'This project is practical within the STS period because it needs literature databases, reference-management software, a spreadsheet, and supervision from my guide. It does not require laboratory work, patient recruitment, or drug administration. Its limits are also clear: published reporting may be incomplete; negative studies may be less likely to be published; assays and constructs differ between papers; and a systemic blood concentration cannot by itself show what concentration reaches the target tissue or whether a switch is activated in a patient. These limitations will be stated alongside the results.' } for p in d.paragraphs: if p.text in replacements: txt=replacements[p.text] for r in p.runs:r.text='' p.runs[0].text=txt # Naturalize table values. cell_repl={ 'Exact chemical is used in both sources; a functional mammalian-cell endpoint and exposure duration are reported; relevant human exposure data are available; and compartments are matched or a published conversion is available.':'The same chemical is used in both sources. The laboratory study reports a functional mammalian-cell endpoint and exposure duration, and a relevant human exposure value is available. The compartments are the same, or a published conversion is available.', 'Exact chemical and functional evidence are available, but a major limitation remains, for example plasma used as a proxy for target tissue, total rather than free concentration, or unmatched duration.':'The same chemical and functional evidence are available, but there is an important limitation. Examples are using plasma as a proxy for target tissue, using total rather than free concentration, or having different exposure durations.', 'Different chemical, metabolite, or analogue is used; only a binding Kd or working concentration is available; no relevant human exposure value exists; or units/compartments cannot be reconciled.':'The laboratory and exposure values refer to different chemicals, metabolites, or analogues; only a binding Kd or a working concentration is reported; no relevant human exposure value is available; or the units and compartments cannot be matched.' } for t in d.tables: for row in t.rows: for c in row.cells: if c.text in cell_repl: c.paragraphs[0].clear();c.paragraphs[0].add_run(cell_repl[c.text]) d.save(out) print(out) PY python3 - <<'PY' from docx import Document p='/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches_Natural_Draft.docx' d=Document(p) text='\n'.join(x.text for x in d.paragraphs) print('paragraphs:',len(d.paragraphs),'tables:',len(d.tables),'words:',len(text.split())) for x in [7,8,9,11,13,21,30,38,41]:print(x,d.paragraphs[x].text[:250]) PY

Running Command

python3 - <<'PY' from docx import Document from pathlib import Path src=Path('/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches.docx') out=Path('/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches_Natural_Draft.docx') d=Document(src) R={ 'Small-molecule-controlled gene switches allow external control of gene expression, protein degradation, apoptosis, or immune-cell activity. Such systems are used in experimental biology and are being developed for cell therapy, gene therapy, engineered immune cells, and implantable designer-cell systems. A practical translational question is whether concentrations of a switch trigger, a related active metabolite, an endogenous molecule, or an environmental analogue that humans may encounter could numerically overlap with concentrations reported to produce functional switch activity in laboratory systems.':'Small-molecule-controlled gene switches are designed to turn a cellular function on or off after exposure to a chosen chemical. Depending on the system, the response may be gene expression, protein degradation, apoptosis, or a change in immune-cell activity. These switches are used in experimental biology and are also being explored for cell therapy, gene therapy, and engineered immune-cell applications. Before such systems are considered for clinical use, it is reasonable to ask whether chemicals already encountered by patients, such as prescribed drugs, metabolites, or naturally occurring molecules, could reach concentrations similar to those used to activate the switch in laboratory studies.', 'This question cannot be answered by simply dividing two numbers. Published functional evidence may be a binding constant, a working concentration, or a concentration-response curve; human exposure may be reported as plasma Cmax, trough, steady-state concentration, endogenous metabolite level, or dietary residue. The source chemical, assay endpoint, duration, units, and compartment may not match. A structured review is therefore needed to identify possible exposure-overlap signals while separating them from comparisons that are invalid or not calculable.':'This is not as simple as dividing one number by another. A switch paper may report a binding constant, a single laboratory working dose, or a proper concentration-response curve. Human exposure can be reported as a peak concentration (Cmax), a trough concentration just before the next dose, a steady-state value, or an endogenous-metabolite level. In many cases the chemical, endpoint, duration of exposure, units, or biological compartment do not match. This review will look for possible exposure-overlap signals, but will also clearly mark comparisons that are too weak or mismatched to calculate.', 'The project is relevant to the safe design of emerging engineered-cell therapies. It does not claim that any switch is unsafe or that unintended activation occurs in humans. It identifies published signals that require construct-specific preclinical pharmacokinetic-pharmacodynamic testing.':'The project is relevant to early safety assessment of engineered-cell therapies. It will not claim that a switch is unsafe or that unintended activation occurs in people. Instead, it will point out which switch-exposure pairs deserve more focused preclinical testing in the relevant construct and cell type.', 'Among mammalian chemical gene switches with therapeutic or translational applications, do published human exposures to the trigger, related active metabolites, endogenous molecules, or environmental analogues overlap with reported functional activation concentrations, and how valid is each quantitative comparison?':'For mammalian chemical gene switches with therapeutic or translational applications, are published human exposure levels of the trigger, related active metabolites, endogenous molecules, or environmental analogues close to concentrations reported to cause functional activation? Where a comparison can be made, how reliable is it?', 'To identify and classify possible overlap between published human chemical-exposure concentrations and published functional activation concentrations of mammalian gene-switch systems, while explicitly documenting the validity and limitations of each comparison.':'To examine whether published human chemical-exposure concentrations may overlap with published functional activation concentrations of mammalian gene-switch systems, and to state clearly how strong or limited each comparison is.', 'To identify published mammalian chemical gene switches with therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or other translational applications.':'To identify published mammalian chemical gene switches that have a therapeutic, implantable-cell, gene-therapy, engineered immune-cell, or other stated translational application.', 'To extract the exact trigger, switch construct, functional endpoint, activation concentration or concentration-response evidence, and exposure duration.':'To record the exact trigger, switch construct, functional endpoint, reported activation concentration or concentration-response data, and duration of exposure.', 'To extract human exposure data for the exact trigger and, where relevant, active metabolites, endogenous counterparts, or environmental analogues.':'To collect human exposure data for the exact trigger and, where relevant, an active metabolite, endogenous counterpart, or environmental analogue.', 'To calculate an exploratory activation-to-exposure ratio only when ligand identity, endpoint, units, and compartment are sufficiently matched.':'To calculate an exploratory activation-to-exposure ratio only when the chemical, endpoint, units, and compartment are sufficiently matched.', 'To classify comparisons as directly comparable, exploratory only, or not calculable, and identify evidence gaps requiring preclinical follow-up.':'To sort comparisons into directly comparable, exploratory only, or not calculable, and identify the missing evidence that prevents a firmer conclusion.', 'Study design: Scoping review with exploratory exposure-overlap screening. The protocol and extraction form will be dated before screening. Reporting will follow PRISMA-ScR principles where applicable.':'Study design: Literature-based scoping review with an exploratory exposure-overlap screen. The protocol and data-extraction form will be finalized before screening starts. The review will be reported using PRISMA-ScR guidance where applicable.', 'Information sources: PubMed, Google Scholar, and Scopus or Web of Science if institutional access is available, from inception to the final search date. Reference lists of eligible studies and key reviews will be screened. Human exposure information will be obtained preferentially from regulatory drug labels and original human pharmacokinetic studies. Data on endogenous compounds or environmental exposures will be extracted from primary human biomonitoring, exposure, or pharmacokinetic studies.':'Information sources: PubMed and Google Scholar will be searched. Scopus or Web of Science will also be used if institutional access is available. Reference lists of included papers and relevant reviews will be checked for additional studies. For prescribed drugs, human exposure information will be taken first from regulatory labels and original pharmacokinetic studies. For endogenous compounds or environmental exposures, primary biomonitoring, exposure, or pharmacokinetic studies will be preferred.', 'Screening: Records will be deduplicated in Zotero. The student will screen titles/abstracts and full texts. The guide will independently verify uncertain full-text decisions and a random 20% of title/abstract decisions. A selection flow diagram will be created.':'Screening: Records will be stored and deduplicated in Zotero. I will screen titles and abstracts first, followed by full texts. My guide will review unclear full-text decisions and a random 20% of title and abstract decisions. A study-selection flow diagram will be included.', 'The ratio will be calculated only for directly comparable or exploratory comparisons. A ratio below 1 will be described as a possible numerical exposure-overlap signal; 1 to 10 as limited numerical separation; and above 10 as greater numerical separation. These categories do not prove activation in humans, clinical risk, safety, or absence of activation. The measure is not a regulatory Margin of Exposure.':'The ratio will only be calculated when the comparison is directly comparable or can reasonably be treated as exploratory. A value below 1 will be described as a possible numerical exposure-overlap signal. A value from 1 to 10 will suggest limited numerical separation, while a value above 10 will suggest greater numerical separation. These labels do not prove activation in humans, clinical risk, safety, or absence of activation. This is an exploratory screening ratio, not a formal regulatory Margin of Exposure.', 'The study is feasible within the STS period because it requires only literature databases, reference-management software, spreadsheet software, and guide supervision. It requires no laboratory work, patient recruitment, or drug administration. Limitations include incomplete reporting, publication bias, variation between assays and constructs, and inability to infer target-tissue exposure or clinical activation from systemic published concentrations. These limitations will be displayed rather than concealed.':'This project is practical within the STS period because it needs literature databases, reference-management software, a spreadsheet, and supervision from my guide. It does not require laboratory work, patient recruitment, or drug administration. Its limits are also clear: published reporting may be incomplete; negative studies may be less likely to be published; assays and constructs differ between papers; and a systemic blood concentration cannot by itself show what concentration reaches the target tissue or whether a switch is activated in a patient. These limitations will be stated alongside the results.'} for p in d.paragraphs: old=p.text if old in R: new=R[old] if p.runs: p.runs[0].text=new for run in p.runs[1:]:run.text='' else:p.add_run(new) # few table cells for t in d.tables: for row in t.rows: for c in row.cells: old=c.text if old.startswith('Exact chemical is used in both sources;'): c.paragraphs[0].runs[0].text='The same chemical is used in both sources. The laboratory study reports a functional mammalian-cell endpoint and exposure duration, and a relevant human exposure value is available. The compartments are the same, or a published conversion is available.' for r in c.paragraphs[0].runs[1:]:r.text='' elif old.startswith('Exact chemical and functional evidence'): c.paragraphs[0].runs[0].text='The same chemical and functional evidence are available, but there is an important limitation, such as using plasma as a proxy for target tissue, using total rather than free concentration, or having different exposure durations.' for r in c.paragraphs[0].runs[1:]:r.text='' elif old.startswith('Different chemical, metabolite, or analogue'): c.paragraphs[0].runs[0].text='The laboratory and exposure values refer to different chemicals, metabolites, or analogues; only a binding Kd or working concentration is reported; no relevant human exposure value is available; or the units and compartments cannot be matched.' for r in c.paragraphs[0].runs[1:]:r.text='' d.save(out) print(out) PY python3 - <<'PY' from docx import Document p='/tmp/workspace/icmr-sts-2027-initial-submission/output/ICMR_STS_2027_Initial_Proposal_Exposure_Overlap_Gene_Switches_Natural_Draft.docx' d=Document(p); text='\n'.join(p.text for p in d.paragraphs) print('paragraphs:',len(d.paragraphs),'tables:',len(d.tables),'words:',len(text.split())) print(d.paragraphs[7].text[:300]) print(d.paragraphs[8].text[:300]) PY

I made the wording more direct and less formulaic while keeping the same research question, methods, and safeguards.

I cannot guarantee how any AI detector will score a document or help bypass one. Before submitting, read it closely and change phrases into your own normal writing style, especially the background, rationale, and why you chose the topic. Your guide should also review the final wording.

ICMR STS 2027 Initial Proposal Exposure Overlap Gene Switches Natural Draft

Word Document · DOCX

Verify this and cross check with our paper

Reading File

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.